Pharmaceutical Research

, Volume 23, Issue 7, pp 1417–1450

Nanotechnology: Intelligent Design to Treat Complex Disease

Expert Review

Abstract

The purpose of this expert review is to discuss the impact of nanotechnology in the treatment of the major health threats including cancer, infections, metabolic diseases, autoimmune diseases, and inflammations. Indeed, during the past 30 years, the explosive growth of nanotechnology has burst into challenging innovations in pharmacology, the main input being the ability to perform temporal and spatial site-specific delivery. This has led to some marketed compounds through the last decade. Although the introduction of nanotechnology obviously permitted to step over numerous milestones toward the development of the “magic bullet” proposed a century ago by the immunologist Paul Ehrlich, there are, however, unresolved delivery problems to be still addressed. These scientific and technological locks are discussed along this review together with an analysis of the current situation concerning the industrial development.

Key Words

autoimmune disease cancer drug targeting infections industrial development liposome metabolic disease nanoparticle vaccine nanotechnology 

References

  1. 1.
    Gregoriadis, G., Wills, E. J., Swain, C. P., Tavill, A. S. 1974Drug carrier potential of liposomes in cancer chemotherapyLancet113131316PubMedCrossRefGoogle Scholar
  2. 2.
    Hu, C., Rhodes, D. G. 2000Proniosomes: a novel drug carrier preparationInt. J. Pharm.206110122PubMedCrossRefGoogle Scholar
  3. 3.
    Jain, K. K. 2005The role of nanobiotechnology in drug discoveryDrug Discov. Today1014351442PubMedCrossRefGoogle Scholar
  4. 4.
    Vasir, J. K., Maram, M. K., Labhasetwar, V. D. 2005Nanosystems in drug targeting: opportunities and challengesCurr. Nanosci.14767CrossRefGoogle Scholar
  5. 5.
    Bianco, A., Hoebeke, J., Godefroy, S., Chaloin, O., Pantarotto, D., Briand, J. P., Muller, S., Prati, M., Partidos, C. D. 2005Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory propertiesJ. Am. Chem. Soc.1275859PubMedCrossRefGoogle Scholar
  6. 6.
    Bianco, A., Costarelos, K., Prato, M. 2005Applications of carbon nanotubes in drug deliveryCurr. Opin. Chem. Biol.9674679PubMedCrossRefGoogle Scholar
  7. 7.
    Venkatesan, N., Yoshimitsu, J., Ito, Y., Shibata, N., Takada, K. 2005Liquid filled nanoparticles as a drug delivery tool for protein therapeuticsBiomaterials2671547163PubMedCrossRefGoogle Scholar
  8. 8.
    Alonso, M. J. 2004Nanomedicine for overcoming biological barriersBiomed. Pharmacother.58168172PubMedCrossRefGoogle Scholar
  9. 9.
    Sykes, R. 2000Towards the magic bulletInt. J. Antimicrob. Agents14112PubMedCrossRefGoogle Scholar
  10. 10.
    Muller, R. H., Jacobs, C., Kayser, O. 2001Nanosuspensions as particulate drug formulations in therapy rational for development and what we can expect for the futureAdv. Drug Deliv. Rev.47319PubMedCrossRefGoogle Scholar
  11. 11.
    Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., Danielsen, M. 1987Lipofection: a highly efficient, lipid-mediated DNA-transfection procedureProc. Natl. Acad. Sci. USA8474137417PubMedCrossRefGoogle Scholar
  12. 12.
    Behr, J. P., Demeneix, B., Loeffler, J. P., Perez-Mutul, J. 1989Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNAProc. Natl. Acad. Sci. USA8669826986PubMedCrossRefGoogle Scholar
  13. 13.
    Krieg, A. M. 2001Immune effects and mechanisms of action of CpG motifsVaccines19618622CrossRefGoogle Scholar
  14. 14.
    Krieg, A. M. 2003CpG motifs: the active ingredient in bacterial extracts?Nat. Med.9831835PubMedCrossRefGoogle Scholar
  15. 15.
    Wang, L., Prekash, R. K., Stein, C. A., Koehn, K. K., Ruffner, D. E. 2003Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivoAntisense Nucleic Acid Drug Dev.13169189PubMedCrossRefGoogle Scholar
  16. 16.
    Hügle, T., Cerny, A. 2003Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitisCrit. Rev. Med. Virol.13361371CrossRefGoogle Scholar
  17. 17.
    Cui, Z. 2005DNA vaccineAdv. Genet.54257289PubMedGoogle Scholar
  18. 18.
    Jain, R. K. 1987Transport of molecules in the tumor interstitium: a reviewCancer Res.4730393051PubMedGoogle Scholar
  19. 19.
    Jain, R. K. 2001Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and functionJ. Control. Release74725PubMedCrossRefGoogle Scholar
  20. 20.
    Links, M., Brown, R. 1999Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugsExpert Rev. Mol. Med.1999121PubMedGoogle Scholar
  21. 21.
    Krishna, R., Mayer, L. D. 2000Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugsEur. J. Pharm. Sci.11265283PubMedCrossRefGoogle Scholar
  22. 22.
    Brigger, I., Dubernet, C., Couvreur, P. 2002Nanoparticles in cancer therapy and diagnosisAdv. Drug Deliv. Rev.54631651PubMedCrossRefGoogle Scholar
  23. 23.
    Kreuter, J., Tauber, U., Illi, V. 1979Distribution and elimination of poly(methyl-2-14C-methacrylate) nanoparticle radioactivity after injection in rats and miceJ. Pharm. Sci.6814431447PubMedGoogle Scholar
  24. 24.
    Keyser, J. L., Poupaert, J. H., Dumont, P. 1991Poly(diethyl methylidenemalonate) nanoparticles as a potential drug carrier: preparation, distribution and elimination after intravenous and peroral administration to miceJ. Pharm. Sci.806770PubMedGoogle Scholar
  25. 25.
    Conley, B. A., Egorin, M. J., Whitacre, M. Y., Carter, D. C., Zuhowski, E. C., Echo, D. A. 1993Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicinCancer Chemother. Pharmacol.33107112PubMedCrossRefGoogle Scholar
  26. 26.
    Chiannilkulchai, N., Ammoury, N., Caillou, B., Devissaguet, J. P., Couvreur, P. 1990Hepatic tissue distribution of doxorubicin-loaded nanoparticles after i.v. administration in reticulosarcoma M 5076 metastasis-bearing miceCancer Chemother. Pharmacol.26122126PubMedCrossRefGoogle Scholar
  27. 27.
    Verdière, A. C., Dubernet, C., Nemati, F., Soma, E., Appel, M., Ferte, J., Bernard, S., Puisieux, F., Couvreur, P. 1997Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of actionBr. J. Cancer76198205PubMedGoogle Scholar
  28. 28.
    Soma, C. E., Dubernet, C., Barratt, G., Nemati, F., Appel, M., Benita, S., Couvreur, P. 1999Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophagesPharm. Res.1617101716PubMedCrossRefGoogle Scholar
  29. 29.
    El-Serag, H. B., Mason, A. C. 1999Rising incidence of hepatocellular carcinoma in the United StatesN. Engl. J. Med.340745750PubMedCrossRefGoogle Scholar
  30. 30.
    Lai, C. L., Wu, P. C., Chan, G. C., Lok, A. S., Lin, H. J. 1988Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trialCancer62479483PubMedCrossRefGoogle Scholar
  31. 31.
    Barraud, L., Merle, P., Soma, E., Lefrançois, L., Guerret, S., Chevallier, M., Dubernet, C., Couvreur, P., Trepo, C., Vitvitski, L. 2005Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivoJ. Hepatol.42736743PubMedCrossRefGoogle Scholar
  32. 32.
    Gabizon, A., Amselem, S., Gorem, D., Cohen, R., Druckmann, S., Fromer, I., Chisin, R., Peretz, A., Barenholz, Y. 1990Preclinical and clinical experience with a doxorubicin liposome preparationJ. Liposome Res.1491502Google Scholar
  33. 33.
    Gabizon, A., Peretz, T., Sulkes, A., Amselem, S., Ben-Yosef, R., Ben-Baruch, N., Catane, R., Biran, S., Barenholz, Y. 1989Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I studyEur. J. Cancer Clin. Oncol.2517951803PubMedCrossRefGoogle Scholar
  34. 34.
    Woodle, M. C., Lasic, D. D. 1992Sterically stabilized liposomesBiochim. Biophys. Acta1113171199PubMedGoogle Scholar
  35. 35.
    Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K., Woodle, M. C., Lasic, D. D., Redemann, C., Martin, M. F. 1991Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacyProc. Natl. Acad. Sci. USA881146011464PubMedCrossRefGoogle Scholar
  36. 36.
    Jeon, S. I., Lee, J. H., Andrade, J. D., Gennes, P. G. 1991Protein–surface interactions in the presence of polyethylene oxide. I Simplified theoryJ. Colloid Interface Sci.142149158CrossRefGoogle Scholar
  37. 37.
    Gabizon, A., Catane, R., Uziely, B., Kaufman, B., Safra, T., Cohen, R., Martin, F., Huang, A., Barenholz, Y. 1994Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomesCancer Res.54987992PubMedGoogle Scholar
  38. 38.
    Illum, L., Jacobsen, L. O., Muller, R. H., Mak, E., Davis, S. S. 1987Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophagesBiomaterials8113117PubMedCrossRefGoogle Scholar
  39. 39.
    Moghimi, S. M., Muir, I. S., Illum, L., Davis, S. S., Kolb-Bachofen, V. 1993Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serumBiochim. Biophys. Acta1179157165PubMedCrossRefGoogle Scholar
  40. 40.
    Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., Langer, R. 1994Biodegradable long-circulating polymeric nanospheresScience26316001603PubMedGoogle Scholar
  41. 41.
    Peracchia, M. T., Harnisch, S., Pinto-Alphandary, H., Gulik, A., Dedieu, J. C., Desmaële, D., D’Angelo, J., Müller, R. H., Couvreur, P. 1999Visualization of in vitro protein-rejecting properties of PEGylated stealth polycyanoacrylate nanoparticleBiomaterials2012691275PubMedCrossRefGoogle Scholar
  42. 42.
    Storm, G., Belliot, S. O., Daemen, T., Lasic, D. D. 1995Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte systemAdv. Drug Deliv. Rev.173148CrossRefGoogle Scholar
  43. 43.
    Moghimi, S. M., Hunter, A. C., Murray, J. C. 2001Long-circulating and target-specific nanoparticles: theory to practicePharmacol. Rev.53283318PubMedGoogle Scholar
  44. 44.
    Dvorak, H. F., Nagy, J. A., Dvorak, J. T., Dvorak, A. M. 1988Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromoleculesAm. J. Pathol.13395109PubMedGoogle Scholar
  45. 45.
    Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., Maeda, H. 1998Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissuesJpn. J. Cancer Res.89307314PubMedGoogle Scholar
  46. 46.
    Maeda, H., Wu, J., Sawa, T., Matsumura, Y., Hori, K. 2000Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a reviewJ. Control. Release65271284PubMedCrossRefGoogle Scholar
  47. 47.
    Calvo, P., Gouritin, B., Villarroya, H., Eclancher, F., Giannavola, C., Klein, C., Andreux, J. P., Couvreur, P. 2002Quantification and localization of PEGylated polycyanoacrylate nanoparticles in brain and spinal cord during experimental allergic encephalomyelitis in the ratEur. J. Neurosci.1513171326PubMedCrossRefGoogle Scholar
  48. 48.
    Rose, P. G. 2005Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancerOncologist10205214PubMedCrossRefGoogle Scholar
  49. 49.
    Gordon, A. N., Granai, C. O., Rose, P. G., Hainsworth, J., Lopez, A., Weissman, C., Rosales, R., Sharpington, T. 2000Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancerJ. Clin. Oncol.1830933100PubMedGoogle Scholar
  50. 50.
    Gordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., Lacave, A. J. 2001Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecanJ. Clin. Oncol.1933123322PubMedGoogle Scholar
  51. 51.
    Lyass, O., Uziely, B., Ben Yosef, R., Tzemach, D., Heshing, N. I., Lotem, M., Brufman, G., Gabizon, A. 2000Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinomaCancer8910371047PubMedCrossRefGoogle Scholar
  52. 52.
    Ferrero, J. M., Weber, B., Lepille, D., Orfeuvre, H., Combe, M., Mayer, F., Leduc, B., Bourgeois, H., Paraiso, D., Pujate-Lauraine, E. 2004Carboplatin (PA) and pegylated liposomal doxorubicin in patients with advanced ovarian cancer in late (>6 months) relapse (AOCLR): survival results of a GINECO phase II trialProc. Am. Soc. Clin. Oncol.23467sGoogle Scholar
  53. 53.
    Sapra, P., Allen, T. M. 2002Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugsCancer Res.6271907194PubMedGoogle Scholar
  54. 54.
    Sapra, P., Allen, T. M. 2003Ligand-targeted liposomal anticancer drugsProg. Lipid Res.42439462PubMedCrossRefGoogle Scholar
  55. 55.
    Torchilin, V. P. 2005Recent advances with liposomes as pharmaceutical carriersNat. Rev. Drug Discov.4145160PubMedCrossRefGoogle Scholar
  56. 56.
    Andresen, T. L., Jensen, S. S., Jorgensen, K. 2005Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug releaseProg. Lipid Res.446897PubMedCrossRefGoogle Scholar
  57. 57.
    Maruyama, K., Ishida, O., Takizawa, T., Moribe, K. 1999Possibility of active targeting to tumor tissues with liposomesAdv. Drug Deliv. Rev.4089102PubMedCrossRefGoogle Scholar
  58. 58.
    Park, J. W., Kirpotin, D. B., Hong, K., Shalaby, R., Shao, Y., Nielsen, U. B., Marks, J. D., Papahadjopoulos, D., Benz, C. C. 2001Tumor targeting using anti-her2 immunoliposomesJ. Control. Release7495113PubMedCrossRefGoogle Scholar
  59. 59.
    Kamps, J. A., Koning, G. A., Velinova, M. J., Morselt, H. W., Wilkens, M., Gorter, A., Donga, J., Scherphof, G. L. 2000Uptake of long-circulating immunoliposomes, directed against colon adenocarcinoma cells, by liver metastases of colon cancerJ. Drug Target.8235245PubMedCrossRefGoogle Scholar
  60. 60.
    Koning, G. A., Morselt, H. W. M., Gorter, A., Allen, T. M., Zalipsky, S., Scherphof, G. L., Kamps, J. A. A. M. 2003Interaction of differently designed immunoliposomes with colon cancer cells and Kupffer cells. An in vitro comparisonPharm. Res.2012491257PubMedCrossRefGoogle Scholar
  61. 61.
    Schiffelers, R. M., Koning, G. A., Hagen, T. L. M., Fens, M. H. A. M., Schraa, A. J., Janssen, A. P. C. A., Kok, R. J., Molema, G., Storm, G. 2003Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicinJ. Control. Release91115122PubMedCrossRefGoogle Scholar
  62. 62.
    Moreira, J. N., Ishida, T., Gaspar, R., Allen, T. M. 2002Use of the post-insertion technique to insert peptide ligands into pre-formed stealth liposomes with retention of binding activity and cytotoxicityPharm. Res.19265269PubMedCrossRefGoogle Scholar
  63. 63.
    Hatakeyama, H., Akita, H., Maruyama, K., Suhara, T., Harashima, H. 2004Factors governing the in vivo tissue uptake of transferrin-coupled polyethylene glycol liposomes in vivoInt. J. Pharm.2812533PubMedCrossRefGoogle Scholar
  64. 64.
    Eavarone, D. A., Yu, X., Bellamkonda, R. V. 2000Targeted drug delivery to C6 glioma by transferrin-coupled liposomesJ. Biomed. Mater. Res.511014PubMedCrossRefGoogle Scholar
  65. 65.
    Ishida, O., Maruyama, K., Tanahashi, H., Iwatsuru, M., Sasaki, K., Eriguchi, M., Yanagie, H. 2001Liposomes bearing polyethyleneglycol-coupled transferrin with intracellular targeting property to the solid tumors in vivoPharm. Res.1810421048PubMedCrossRefGoogle Scholar
  66. 66.
    Lee, R. J., Low, P. S. 1994Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosisJ. Biol. Chem.26931983204PubMedGoogle Scholar
  67. 67.
    Ni, S., Stephenson, S. M., Lee, R. J. 2002Folate receptor targeted delivery of liposomal daunorubicin into tumor cellsAnticancer Res.2221312135PubMedGoogle Scholar
  68. 68.
    Pan, X. Q., Wang, H., Lee, R. J. 2003Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft modelPharm. Res.20417422PubMedCrossRefGoogle Scholar
  69. 69.
    Sudimack, J. J., Adams, D., Rotaru, J., Shukla, S., Yan, J., Sekido, M., Barth, R. F., Tjarks, W., Lee, R. J. 2002Folate receptor-mediated liposomal delivery of a lipophilic boron agent to tumor cells in vitro for neutron capture therapyPharm. Res.1915021508PubMedCrossRefGoogle Scholar
  70. 70.
    Opanasopit, P., Sakai, M., Nishikawa, M., Kawakami, S., Yamashita, F., Hashida, M. 2002Inhibition of liver metastasis by targeting of immunomodulators using mannosylated liposome carriersJ. Control. Release80283294PubMedCrossRefGoogle Scholar
  71. 71.
    Stella, B., Arpicco, S., Peracchia, M. T., Desmaele, D., Hoebeke, J., Renoir, M., D’Angelo, J., Cattel, L., Couvreur, P. 2000Design of folic acid-conjugated nanoparticles for drug targetingJ. Pharm. Sci.8914521464PubMedCrossRefGoogle Scholar
  72. 72.
    Wartlick, H., Michaelis, K., Balthasar, S., Strebhardt, K., Kreuter, J., Langer, K. 2004Highly specific HER2-mediated cellular uptake of antibody-modified nanoparticles in tumour cellsJ. Drug Target.12461471PubMedCrossRefGoogle Scholar
  73. 73.
    Yatvin, M. B., Kreutz, W., Horwitz, B. A., Shinitzky, M. 1980pH-sensitive liposomes: possible clinical implicationsScience21012531255PubMedGoogle Scholar
  74. 74.
    Shin, J., Shum, P., Thompson, D. H. 2003Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipidsJ. Control. Release91187200PubMedCrossRefGoogle Scholar
  75. 75.
    Helmlinger, G., Yuan, F., Dellian, M., Jain, R. K. 1997Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlationNat. Med.3177182PubMedCrossRefGoogle Scholar
  76. 76.
    Helmlinger, G., Sckell, A., Dellian, M., Forbes, N. S., Jain, R. K. 2002Acid production in glycolysis-impaired tumors provides new insights into tumor metabolismClin. Cancer Res.812841291PubMedGoogle Scholar
  77. 77.
    Fattal, E., Couvreur, P., Dubernet, C. 2004“Smart” delivery of antisense oligonucleotides by anionic pH-sensitive liposomesAdv. Drug Deliv. Rev.56931946PubMedCrossRefGoogle Scholar
  78. 78.
    Simoes, S., Moreira, J. N., Fonseca, C., Düzgünes, N., Pedroso de Lima, M. C. 2004On the formulation of pH-sensitive liposomes with long circulation timesAdv. Drug Deliv. Rev.56947965PubMedCrossRefGoogle Scholar
  79. 79.
    Mori, A., Klibanov, A. L., Torchilin, V. P., Huang, L. 1991Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivoFEBS Lett.284263266PubMedCrossRefGoogle Scholar
  80. 80.
    Kono, K., Zenitani, K., Takagishi, T. 1994Novel pH-sensitive liposomes: liposomes bearing a poly(ethylene glycol) derivative with carboxyl groupsBiochim. Biophys. Acta119319PubMedCrossRefGoogle Scholar
  81. 81.
    Roux, E., Francis, M., Winnik, F. M., Leroux, J. C. 2002Polymer based pH-sensitive carriers as a means to improve the cytoplasmic delivery of drugsInt. J. Pharm.2422536PubMedCrossRefGoogle Scholar
  82. 82.
    Collins, D., Litzinger, D. C., Huang, L. 1990Structural and functional comparisons of pH-sensitive liposomes composed of phosphatidylethanolamine and three different diacylsuccinylglycerolsBiochim. Biophys. Acta1025234242PubMedCrossRefGoogle Scholar
  83. 83.
    Kono, K., Igawa, T., Takagishi, T. 1997Cytoplasmic delivery of calcein mediated by liposomes modified with a pH-sensitive poly(ethylene glycol) derivativeBiochim. Biophys. Acta1325143154PubMedCrossRefGoogle Scholar
  84. 84.
    Slepushkin, V. A., Simoens, S., Dazin, P., Newman, M. S., Guo, L. S., Pedroso de Lima, M. C., Duzgunes, N. 1997Sterically stabilized pH-sensitive liposomes. Intracellular delivery of aqueous contents and prolonged circulation in vivoJ. Biol. Chem.27223822388PubMedCrossRefGoogle Scholar
  85. 85.
    Liu, D., Huang, L. 1990pH-Sensitive, plasma-stable liposomes with relatively prolonged residence in circulationBiochim. Biophys. Acta1022348354PubMedCrossRefGoogle Scholar
  86. 86.
    Yatvin, M. B., Weinstein, J. N., Dennis, W. H., Blumenthal, R. 1978Design of liposomes for enhanced local release of drugs by hyperthermiaScience20212901293PubMedGoogle Scholar
  87. 87.
    Kong, G., Anyarambhatla, G., Petros, W. P., Braun, R. D., Colvin, O. M., Needham, D., Dewhirst, M. W. 2000Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug releaseCancer Res.6069506957PubMedGoogle Scholar
  88. 88.
    Needham, D., Anyarambhatla, G., Kong, G., Dewhirs, M. W. 2000A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft modelCancer Res.6011971201PubMedGoogle Scholar
  89. 89.
    Andresen, T. L., Davidsen, J., Begtrup, M., Mouritsen, O. G., Jorgensen, K. 2004Enzymatic release of antitumor ether lipids by specific phospholipase A2 activation of liposome-forming prodrugsJ. Med. Chem.4716941703PubMedCrossRefGoogle Scholar
  90. 90.
    Andresen, T. L., Mouritsen, O. G., Begtrup, M., Jorgensen, K. 2002Phospholipase A2 activity: dependence on liposome surface charge and polymer coverageBiophys. J.82148cGoogle Scholar
  91. 91.
    Pak, C. C., Erukulla, R. K., Ahl, P. L., Janoff, A. S., Meers, P. 1999Elastase activated liposomal delivery to nucleated cellsBiochim. Biophys. Acta1419111126PubMedCrossRefGoogle Scholar
  92. 92.
    Davis, S. C., Szoka, F. C.,Jr. 1998Cholesterol phosphate derivatives: synthesis and incorporation into a phosphatase and calcium-sensitive triggered release liposomeBioconjug. Chem.9783792PubMedCrossRefGoogle Scholar
  93. 93.
    Mueller, A., Bondurant, B., O’Brien, D. F. 2000Visible-light stimulated destabilization of PEG-liposomesMacromolecules3347994804CrossRefGoogle Scholar
  94. 94.
    Bonnemain, B. 1998Superparamagnetic agents in magnetic resonance imaging: physicochemical characteristics and clinical applications. A reviewJ. Drug Target.6167174PubMedCrossRefGoogle Scholar
  95. 95.
    Pouliquen, D., Jeune, J. J., Perdrisot, R., Ermias, A., Jallet, P. 1991Iron oxide nanoparticles for use as an MRI contrast agent: pharmacokinetics and metabolismMagn. Reson. Imaging9275283PubMedCrossRefGoogle Scholar
  96. 96.
    Okon, E., Pouliquen, D., Okon, P., Kovaleva, Z. V., Stepanova, T. P., Lavit, S. G., Kudryavtsev, B. N., Jallet, P. 1994Biodegradation of magnetite dextran nanoparticles in the rat. A histologic and biophysical studyLab. Invest.71895903PubMedGoogle Scholar
  97. 97.
    Chachuat, A., Bonnemain, B. 1995European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patientsRadiology35S274S276Google Scholar
  98. 98.
    Kubaska, S., Sahani, D. V., Saini, S., Hahn, P. F., Halpern, E. 2001Dual contrast enhanced magnetic resonance imaging of the liver with superparamagnetic iron oxide followed by gadolinium for lesion detection and characterisationClin. Radiol.56410415PubMedCrossRefGoogle Scholar
  99. 99.
    Weissleder, R., Elizondo, G., Stark, D. D., Hahn, P. F., Marfil, J., Gonzalez, J. F., Saini, S., Todd, L. E., Ferrucci, J. T. 1989The diagnosis of splenic lymphoma by MR imaging: value of superparamagnetic iron oxideA.J.R. Am. J. Roentgenol.152175180Google Scholar
  100. 100.
    Iannone, A., Magin, R. L., Walczak, T., Federico, M., Swartz, H. M., Tomasi, A., Vannini, V. 1991Blood clearance of dextran magnetite particles determined by a noninvasive in vivo ESR methodMagn. Reson. Med.22435442PubMedGoogle Scholar
  101. 101.
    Weissleder, R., Bogdanov, A., Neuwelt, E. A., Papisov, M. 1995Long-circulating iron oxides for MR imagingAdv. Drug Deliv. Rev.16321334CrossRefGoogle Scholar
  102. 102.
    Turetschek, K., Huber, S., Floyd, E., Helbich, T., Roberts, T. P., Shames, D. M., Tarlo, K. S., Wendland, M. F., Brasch, R. C. 2001MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlationRadiology218562569PubMedGoogle Scholar
  103. 103.
    Anzai, Y., McLachlan, S., Morris, M., Saxton, R., Lufkin, R. B. 1994Dextran-coated superparamagnetic iron oxide, an MR contrast agent for assessing lymph nodes in the head and neckAm. J. Neuroradiol.158794PubMedGoogle Scholar
  104. 104.
    Lind, K., Kresse, M., Debus, N. P., Muller, R. H. 2002A novel formulation for superparamagnetic iron oxide (SPIO) particles enhancing MR lymphograpy: comparison of physicochemical properties and the in vivo behaviourJ. Drug Target.10221230PubMedCrossRefGoogle Scholar
  105. 105.
    Moore, A., Weissleder, R., Bogdanov, A.,Jr. 1997Uptake of dextran-coated monocrystalline iron oxides in tumor cells and macrophagesJ. Magn. Reson. Imaging711401145PubMedGoogle Scholar
  106. 106.
    Moore, A., Basilion, J. P., Chiocca, E. A., Weissleder, R. 1998Measuring transferrin receptor gene expression by NMR imagingBiochim. Biophys. Acta1402239249PubMedCrossRefGoogle Scholar
  107. 107.
    Varallyay, P., Nesbit, G., Muldoon, L. L., Nixon, R. R., Delashaw, J., Cohen, J. I., Petrillo, A., Rink, D., Neuwelt, E. A. 2002Comparison of two superparamagnetic viral-sized iron oxide particles ferumoxides and ferumoxtran-10 with a gadolinium chelate in imaging intracranial tumorsAm. J. Neuroradiol.23510519PubMedGoogle Scholar
  108. 108.
    Remsen, L. G., McCormick, C. I., Roman-Goldstein, S., Nilaver, G., Weissleder, R., Bogdanov, A., Hellstrom, I., Kroll, R. A., Neuwelt, E. A. 1996MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanoparticles: the potential for noninvasive diagnosisAm. J. Neuroradiol.17411418PubMedGoogle Scholar
  109. 109.
    Artemov, D., Mori, N., Okollie, B., Bhujwalla, Z. M. 2003MR molecular imaging of the Her-2/neu receptor in breast cancer cells using targeted iron oxide nanoparticlesMagn. Reson. Med.49403408PubMedCrossRefGoogle Scholar
  110. 110.
    Shinkai, M., Yanase, M., Suzuki, M., Honda, H., Wakabayashi, T., Yoshida, J., Kobayashi, T. 1999Intracellular hyperthermia for cancer using magnetite cationic liposomesJ. Magn. Magn. Mater.194176184CrossRefGoogle Scholar
  111. 111.
    Yanase, M., Shinkai, M., Honda, H., Wakabayashi, T., Yoshida, J., Kobayashi, T. 1998Antitumor immunity induction by intracellular hyperthermia using magnetite cationic liposomesJpn. J. Cancer Res.89775782PubMedGoogle Scholar
  112. 112.
    Hilger, I., Andrä, W., Hergt, R., Hiergeist, R., Schubert, H., Kaiser, W. A. 2001Electromagnetic heating of breast tumors in interventional radiology: in vitro and in vivo studies in human cadavers and miceRadiology218570575PubMedGoogle Scholar
  113. 113.
    Jordan, A., Wust, P., Scholz, R., Faehling, H., Krause, J., Felix, R. 1997

    Magnetic fluid hyperthermia (MFH)

    Hafeli, U.Schutt, W.Teller, J.Hdfeli, U.Schutt, W.Zborowski, M. eds. Scientific and Clinical Applications of Magnetic CarriersPlenum PressNew York569595
    Google Scholar
  114. 114.
    Jordan, A., Scholz, R., Maier-Hauff, K., Johannsen, M., Wust, P., Nadobny, J., Schirra, H., Schmidt, H., Deger, S., Loening, S., Lanksch, W., Felix, R. 2001Presentation of a new magnetic field therapy system for the treatment of human solid tumors with magnetic fluid hyperthermiaJ. Magn. Magn. Mater.225118126CrossRefGoogle Scholar
  115. 115.
    Halbreich, A., Roger, J., Pons, J. N., Geldwerth, D., Silva, M. F., Roudier, M., Bacri, J. C. 1998Biomedical applications of maghemite ferrofluidBiochimie80379390PubMedCrossRefGoogle Scholar
  116. 116.
    Bacri, J. C., Silva, M. F., Perzynski, R., Pons, J. N., Roger, J., Sabolovic, D., Halbreich, A. 1997

    Use of magnetic nanoparticles for thermolysis of cells in a ferrofluid

    Hafeli, U.Schutt, W.Teller, J.Hdfeli, U.Schutt, W.Zborowski, M. eds. Scientific and Clinical Applications of Magnetic CarriersPlenum PressNew York597606
    Google Scholar
  117. 117.
    Jordan, A., Scholz, R., Wust, P., Schirra, H. 1999Endocytosis of dextran and silan-coated magnetite nanoparticles and the effect of intracellular hyperthermia on human mammary carcinoma cells in vitroJ. Magn. Magn. Mater.194185196CrossRefGoogle Scholar
  118. 118.
    Shinkai, M., Le, B., Honda, H., Yoshikawa, K., Shimizu, K., Saga, S., Wakabayashi, T., Yoshida, J., Kobayashi, T. 2001Targeting hyperthermia for renal cell carcinoma using human MN antigen-specific magnetoliposomesJpn. J. Cancer Res.9211381145PubMedGoogle Scholar
  119. 119.
    Sonvico, F., Mornet, S., Vasseur, S., Dubernet, C., Jaillard, D., Degrouard, J., Hoebeke, J., Duguet, E., Colombo, P., Couvreur, P. 2005Folate-conjugated iron oxide nanoparticles for solid tumor targeting as potential “Specific Magnetic Hyperthermia Mediators: Synthesis, Physicochemical Characterization, and in Vitro Experiments”Bioconjug. Chem.1611811188PubMedCrossRefGoogle Scholar
  120. 120.
    Pitsillides, C. M., Joe, E. K., Wie, X., Anderson, R. R., Lin, C. P. 2003Selective cell targeting with light-adsorbing microparticles and nanoparticlesBiophys. J.8440234032PubMedCrossRefGoogle Scholar
  121. 121.
    Lin, C. P., Kelly, M. W., Sibayan, S. A., Latina, M. A., Anderson, R. R. 1999Selective cell killing by microparticle absorption of pulsed laser radiationIEEE J. Sel. Top. Quantum Electron.5963968CrossRefGoogle Scholar
  122. 122.
    Shi, F., Rakhmilevich, A. L., Heise, C. P., Oshikawa, K., Sondel, P. M., Yang, N. S., Mahvi, D. M. 2002Intratumoral injection of interleukin-12 plasmid DNA, either naked or in complex with cationic lipid, results in similar tumor regression in a murine modelMol. Cancer Ther.1949957PubMedGoogle Scholar
  123. 123.
    Kawabata, K., Takakura, T., Hashida, M. 1995The fate of plasmid DNA after intravenous injection in mice: involvement of scavenger receptors in its hepatic uptakePharm. Res.12825830PubMedCrossRefGoogle Scholar
  124. 124.
    Ewert, K., Ahmad, A., Evans, H. M., Schmidt, H. W., Safinya, C. R. 2002Efficient synthesis and cell-transfection properties of a new multivalent cationic lipid for nonviral gene deliveryJ. Med. Chem.4550235029PubMedCrossRefGoogle Scholar
  125. 125.
    Gao, H., Hui, K. M. 2001Synthesis of a novel series of cationic lipids that can act as efficient gene delivery vehicles through systematic heterocyclic substitution of cholesterol derivativesGene Ther.8855863PubMedCrossRefGoogle Scholar
  126. 126.
    Gao, X., Huang, L. 1996Potentiation of cationic liposome-mediated gene delivery by polycationsBiochemistry3510271036PubMedCrossRefGoogle Scholar
  127. 127.
    Ueno, N. T., Bartholomeusz, C., Xia, W., Anklesaria, P., Bruckheimer, E. M., Mebel, E., Paul, R., Li, S., Yo, G. H., Huang, L., Hung, M. C. 2002Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A geneCancer Res.6267126716PubMedGoogle Scholar
  128. 128.
    Nikitin, A. Y., Juarez-Perez, M. I., Li, S., Huang, L., Lee, W. H. 1999RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/− miceProc. Natl. Acad. Sci. USA9639163921PubMedCrossRefGoogle Scholar
  129. 129.
    Wyman, T. B., Nicol, F., Zelphati, O., Scaria, P. V., Plank, C., Szoka, F. C.,Jr. 1997Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayersBiochemistry3630083017PubMedCrossRefGoogle Scholar
  130. 130.
    Wu, G. Y., Wu, C. H. 1987Receptor-mediated in vitro gene transformation by a soluble DNA carrier systemJ. Biol. Chem.26244294432PubMedGoogle Scholar
  131. 131.
    Ward, C. M., Read, M. L., Seymour, L. W. 2001Systemic circulation of poly(l-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapyBlood9722212229PubMedCrossRefGoogle Scholar
  132. 132.
    Boussif, O., Lezoualc’h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., Behr, J. P. 1995A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimineProc. Natl. Acad. Sci. USA9272977301PubMedCrossRefGoogle Scholar
  133. 133.
    Kichler, A., Leborgne, C., Coeytaux, E., Danos, O. 2001Polyethylenimine-mediated gene delivery: a mechanistic studyJ. Gene Med.3135144PubMedCrossRefGoogle Scholar
  134. 134.
    Lee, H., Jeong, J. H., Park, T. G. 2002PEG grafted polylysine with fusogenic peptide for gene delivery: high transfection efficiency with low cytotoxicityJ. Control. Release79283291PubMedCrossRefGoogle Scholar
  135. 135.
    Wagner, E., Zenke, M., Cotten, M., Beug, H., Birnstiel, M. L. 1990Transferrin-polycation conjugates as carriers for DNA uptake into cellsProc. Natl. Acad. Sci. USA8734103414PubMedCrossRefGoogle Scholar
  136. 136.
    Suh, W., Chung, J. K., Park, S. H., Kim, S. W. 2001Anti-JL1 antibody-conjugated poly(l-lysine) for targeted gene delivery to leukemia T cellsJ. Control. Release72171178PubMedCrossRefGoogle Scholar
  137. 137.
    Ward, C. M., Pechar, M., Oupicky, D., Ulbrich, K., Seymour, L. W. 2002Modification of pLL/DNA complexes with a multivalent hydrophilic polymer permits folate-mediated targeting in vitro and prolonged plasma circulation in vivoJ. Gene Med.4536547PubMedCrossRefGoogle Scholar
  138. 138.
    Kircheis, R., Schuller, S., Brunner, S., Ogris, M., Heider, K. H., Zauner, W., Wagner, E. 1999Polycation-based DNA complexes for tumor-targeted gene delivery in vivoJ. Gene Med.1111120PubMedCrossRefGoogle Scholar
  139. 139.
    Stingl, G., Brocker, E. B., Mertelsmann, R., Wolff, K., Schreiber, S., Kampgen, E., Schneeberger, A., Dummer, W., Brennscheid, U., Veelken, H., Birnstiel, M. L., Zatloukal, K., Schmidt, W., Maass, G., Wagner, E., Baschle, M., Giese, M., Kempe, E. R., Weber, H. A., Voigt, T. 1996Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 geneHum. Gene Ther.7551563PubMedGoogle Scholar
  140. 140.
    Chen, J., Gamou, S., Takayanagi, A., Shimizu, N. 1994A novel gene delivery system using EGF receptor-mediated endocytosisFEBS Lett.338167169PubMedCrossRefGoogle Scholar
  141. 141.
    Boletta, A., Benigni, A., Lutz, J., Remuzzi, G., Soria, M. R., Monaco, L. 1997Nonviral gene delivery to the rat kidney with polyethylenimineHum. Gene Ther.812431251PubMedGoogle Scholar
  142. 142.
    Köping-Höggard, M., Mel’nikova, Y. S., Varum, K. M., Lindman, B., Artursson, P. 2003Relationship between the physical shape and the efficiency of oligomeric chitosan as a gene delivery system in vitro and in vivoJ. Gene Med.5130141PubMedCrossRefGoogle Scholar
  143. 143.
    Vincent, L., Varet, J., Pille, J. Y., Bompais, H., Opolon, P., Maksimenko, A., Malvy, C., Mirshahi, M., Lu, H., Vannier, J. P., Soria, C., Li, H. 2003Efficacy of dendrimer-mediated angiostatin and TIMP-2 gene delivery on inhibition of tumor growth and angiogenesis: in vitro and in vivo studiesInt. J. Cancer.105419429PubMedCrossRefGoogle Scholar
  144. 144.
    Wetering, P., Cherng, J. Y., Talsma, H., Hennink, W. E. 1997Relation between transfection efficiency and cytotoxicity of poly(2-(dimethylamino)ethyl methacrylate)/plasmid complexesJ. Control. Release495969CrossRefGoogle Scholar
  145. 145.
    El-Aneed, A. 2004An overview of current delivery systems in cancer gene therapyJ. Control. Release94114PubMedCrossRefGoogle Scholar
  146. 146.
    Chavany, C., Saison-Behmoaras, T., Doan, T., Puisieux, F., Couvreur, P., Hélène, C. 1994Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increase their cellular uptakePharm. Res.1113701378PubMedCrossRefGoogle Scholar
  147. 147.
    Schwab, G., Chavany, C., Duroux, I., Goubin, G., Lebeau, J., Hélène, C., Saison-Behmoaras, T. 1994Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude miceProc. Natl. Acad. Sci. USA911046010464PubMedCrossRefGoogle Scholar
  148. 148.
    Tondelli, L., Ricca, A., Laus, M., Lelli, M., Citro, G. 1998Highly efficient cellular uptake of c-myb antisense oligonucleotides through specifically designed polymeric nanospheresNucleic Acids Res.2654255431PubMedCrossRefGoogle Scholar
  149. 149.
    Thierry, A. R., Rahman, A., Dritschilo, A. 1993Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynucleotidesBiochem. Biophys. Res. Commun.190952960PubMedCrossRefGoogle Scholar
  150. 150.
    Vinogradov, S., Batrakova, E., Kabanov, A. 1999Poly(ethylene glycol)–polyethyleneimine NanoGel TM particles: novel drug delivery systems for antisense oligonucleotidesColloids Surf., B Biointerfaces16291304CrossRefGoogle Scholar
  151. 151.
    May, W. A., Gishizky, M. L., Lessnick, S. L., Lunsford, L. B., Lewis, B. C., Delattre, O., Zucman, J., Thomas, G., Dennt, C. T. 1993Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformationProc. Natl. Acad. Sci. USA9057525756PubMedCrossRefGoogle Scholar
  152. 152.
    Tanaka, K., Iwakuma, T., Harimaya, K., Sato, H., Iwamoto, Y. 1997EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cellsJ. Clin. Invest.99239247PubMedCrossRefGoogle Scholar
  153. 153.
    Lambert, G., Bertrand, J. R., Fattal, E., Subra, F., Pinto-Alphandary, H., Malvy, C., Auclair, C., Couvreur, P. 2000EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in miceBiochem. Biophys. Res. Commun.279401406PubMedCrossRefGoogle Scholar
  154. 154.
    Maksimenko, A., Malvy, C., Lambert, G., Bertrand, J. R., Fattal, E., Maccario, J., Couvreur, P. 2003Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologiesPharm. Res.2015651567PubMedCrossRefGoogle Scholar
  155. 155.
    Toub, N., Angiari, C., Eboué, D., Fattal, E., Tenu, J. P., Doan, T., Couvreur, P. 2005Cellular fate of oligonucleotides when delivered by nanocapsules of poly(isobutylcyanoacrylate)J. Control. Release106209213PubMedCrossRefGoogle Scholar
  156. 156.
    Hassani, Z., Lemkine, G. F., Erbacher, P., Palmier, K., Alfama, G., Giovannangeli, C., Behr, J. P., Demeneix, B. A. 2005Lipid-mediated siRNA delivery down-regulates exogenous gene expression in the mouse brain at picomolar levelsJ. Gene Med.7198207PubMedCrossRefGoogle Scholar
  157. 157.
    Zhang, Y., Zhang, Y. F., Bryant, J., Charles, A., Boado, R. J., Pardridge, W. M. 2004Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancerClin. Cancer Res.10 36673677PubMedCrossRefGoogle Scholar
  158. 158.
    World Health Organisation. Number of Confirmed Cases of Poliomyelitis 2002–2005 (as of 12 September 2005), http://www.emro.who.int/polio/ (accessed 16 September 2005), part of http://www.who.int (accessed 16 September 2005).
  159. 159.
    World Health Organisation. Smallpox, http://www.who.int/topics/smallpox/en/ (accessed 16 September 2005), part of http://www.who.int (accessed 16 September 2005).
  160. 160.
    Maesaki, S. 2002Drug delivery system of anti-fungal and parasitic agentsCurr. Pharm. Des.8433440PubMedCrossRefGoogle Scholar
  161. 161.
    Dupont, B. 2002Overview of the lipid formulations of amphothericin BJ. Antimicrob. Chemother.493136PubMedCrossRefGoogle Scholar
  162. 162.
    Ringden, O. 2002Ten years' experience with liposomal amphotericin B in transplant recipients at Huddinge University HospitalJ. Antimicrob. Chemother.495155PubMedGoogle Scholar
  163. 163.
    Croft, S. L., Coombs, G. H. 2003Leishmaniasis-current chemotherapy and recent advances in the search for novel drugsTrends Parasitol.19502508PubMedCrossRefGoogle Scholar
  164. 164.
    Ng, A. W. K., Wasan, K. M. 2003Development of liposomal polyene antibiotics: an historical perspectiveJ. Pharm. Pharm. Sci.66783PubMedGoogle Scholar
  165. 165.
    Gibbs, W. J., Drew, R. H., Perfect, J. R. 2005Liposomal amphotericin B: clinical experience and perspectivesExpert Rev. Anti-infect. Ther.3167181PubMedCrossRefGoogle Scholar
  166. 166.
    Owais, M., Varshney, G. C., Choudhury, A., Chandra, S., Gupta, C. M. 1995Chloroquine encapsulated in malaria-infected erythrocyte-specific antibody-bearing liposomes effectively controls chloroquine-resistant Plasmodium berghei infections in miceAntimicrob. Agents. Chemother.39180184PubMedGoogle Scholar
  167. 167.
    Adler-Moore, J. P., Proffitt, R. T. 1993Development, characterization, efficacy and mode of action of Ambisome®, a unilamellar liposome formulation of amphotericin BJ. Liposome Res.3429450Google Scholar
  168. 168.
    Murray, H. W. 2004Progress in the treatment of a neglected infectious disease: visceral leishmaniasisExpert Rev. Anti-infect. Ther.2279292PubMedCrossRefGoogle Scholar
  169. 169.
    Murray, H. W. 2004Treatment of visceral leishmaniasis in 2004Am. J. Trop. Med. Hyg.71787794PubMedGoogle Scholar
  170. 170.
    Larabi, M., Yardley, V., Loiseau, P. M., Appel, M., Legrand, P., Gulik, A., Boris, C., Croft, S., Barratt, G. 2003Toxicity and antileishmanial activity of a new stable lipid suspension of amphothericin BAntimicrob. Agents Chemother.4737743779PubMedCrossRefGoogle Scholar
  171. 171.
    Basu, M. K., Lala, S. 2004Macrophage specific drug delivery in experimental leishmaniasisCurr. Mol. Med.4681689PubMedCrossRefGoogle Scholar
  172. 172.
    Legrand, P., Barratt, G., Mosqueira, V., Fessi, H., Devissaguet, J. P. 1999Polymeric nanocapsules as drug delivery systems: a reviewSci. Tech. Pharm.9411418Google Scholar
  173. 173.
    Gaspar, R., Preat, V., Opperdoes, F. R., Rolland, M. 1992Macrophage activation by polymeric nanoparticles of polyalkylcyanoacrylates: activity against intracellular Leishmania donovani associated with hydrogen peroxide productionPharm. Res.9782787PubMedCrossRefGoogle Scholar
  174. 174.
    Fouarge, M., Dewulf, M., Couvreur, P., Rolland, M., Vranckx, H. 1989Development of dehydroemetine nanoparticles for the treatment of visceral leishmaniasisJ. Microencapsul.62934PubMedGoogle Scholar
  175. 175.
    Espuelas, M. S., Legrand, P., Campanero, M. A., Appel, M., Chéron, M., Gamazo, C., Barratt, G., Irache, J. M. 2003Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic miceJ. Antimicrob. Chemother.52419427PubMedCrossRefGoogle Scholar
  176. 176.
    Tyagi, R., Lala, S., Verma, A. K., Nandy, A. K., Mahato, S. B., Maitra, A., Basu, M. K. 2005Targeted delivery of arjunglucoside I using surface hydrophilic and hydrophobic nanocarriers to combat experimental leishmaniasisJ. Drug Target.13161171PubMedGoogle Scholar
  177. 177.
    Mosqueira, V. C. F., Loiseau, P. M., Bories, C., Legrand, P., Devissaguet, J. P., Barratt, G. 2004Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected miceAntimicrob. Agents Chemother.4812221228PubMedCrossRefGoogle Scholar
  178. 178.
    Bakker-Woudenberg, I. A. 2002Long-circulating sterically stabilized liposomes as carriers of agents for treatment of infection or for imaging infectious fociInt. J. Antimicrob. Agents19299311PubMedCrossRefGoogle Scholar
  179. 179.
    Pinto-Alphandary, H., Andremont, A., Couvreur, P. 2000Targeted delivery of antibiotics using liposomes and nanoparticles: research and applicationsInt. J. Antimicrob. Agents13155168PubMedCrossRefGoogle Scholar
  180. 180.
    Schiffelers, R., Storm, G., Bakker-Woudenberg, I. 2001Liposome-encapsulated aminoglycosides in pre-clinical and clinical studiesJ. Antimicrob. Chemother.48333344PubMedCrossRefGoogle Scholar
  181. 181.
    Barratt, G. 2004Colloidal drug carriers: achievements and perspectivesCell. Mol. Life Sci.602137CrossRefGoogle Scholar
  182. 182.
    Fielding, R. M., Lewis, R. O., Moon-McDermott, L. 1998Altered tissue distribution and elimination of Amikacin encapsulated in unilamellar, low clearance liposomes (Mikasome®)Pharm. Res.1517751781PubMedCrossRefGoogle Scholar
  183. 183.
    Fielding, R. M., Moon-McDermott, L., Lewis, R. O., Horner, M. J. 1999Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkeyAntimicrob. Agents Chemother.43503509PubMedCrossRefGoogle Scholar
  184. 184.
    Donald, P. R., Sirgel, F. A., Venter, A., Smit, E., Parkin, D. P., Wal, B. W., Mitchison, D. A. 2001The early bactericidal activity of a low-clearance liposomal amikacin in pulmonary tuberculosisJ. Antimicrob. Chemother.48877880PubMedCrossRefGoogle Scholar
  185. 185.
    Fattal, E., Youssef, M., Couvreur, P., Andremont, A. 1989Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticlesAntimicrob. Agents Chemother.33 15401543PubMedGoogle Scholar
  186. 186.
    Fattal, E., Rojas, J., Youssef, M., Couvreur, P., Andremont, A. 1991Liposome-entrapped ampicillin in the treatment of experimental murine listeriosis and salmonellosisAntimicrob. Agents Chemother.35770772PubMedGoogle Scholar
  187. 187.
    Fattal, E., Balland, O., Alphandary, H., Pecquet, S., Puisieux, F., Couvreur, P., Andremont, A. 1993

    Colloidal carriers of antibiotics as an alternative approach for the treatment of intracellular infections

    Raoult, D. eds. Antimicrobial Agents and Intracellular PathogensCRC PressBoca Raton, FL6372
    Google Scholar
  188. 188.
    Yousseff, M., Fattal, E., Alonso, M. J., Roblot-Treupel, L., Sauzières, J., Tancrède, C., Omnes, A., Couvreur, P., Andremont, A. 1988Effectiveness of nanoparticle-bound ampicillin in the treatment of Listeria monocytogenes infection in athymic nude miceAntimicrob. Agents Chemother.3212041207Google Scholar
  189. 189.
    Page-Clisson, M. E., Pinto-Alphandary, H., Chachaty, E., Couvreur, P., Andremont, A. 1998Drug targeting by polyalkylcyanoacrylate is not efficient against persistent SalmonellaPharm. Res.15542547Google Scholar
  190. 190.
    Zhang, Y. 2005The magic bullets and tuberculosis targetsAnnu. Rev. Pharmacol. Toxicol.45529564PubMedCrossRefGoogle Scholar
  191. 191.
    Vitas, A. I., Diaz, R., Gamazo, C. 1996Effect on composition and method of preparation of liposomes on their stability and interaction with murine monocytes infected with Brucella abortusAntimicrob. Agents Chemother.40146151PubMedGoogle Scholar
  192. 192.
    Engel, A., Kumar Chatterjee, S., Al-Arifi, A., Riemann, D., Laugner, J., Nuhn, P. 2003Influence of spacer length in interaction of mannosylated liposomes with human phagocytic cellsPharm. Res.205157PubMedCrossRefGoogle Scholar
  193. 193.
    Anderson, K. E., Eliot, L. A., Stevenson, B. R., Rogers, J. A. 2001Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage formPharm. Res.18316322PubMedCrossRefGoogle Scholar
  194. 194.
    Price, C. I., Horton, J. W., Baxter, C. R. 1994Liposome encapsulation: a method for enhancing the effectiveness of local antibioticsSurgery115480487PubMedGoogle Scholar
  195. 195.
    Sanderson, N. M., Jones, M. N. 1996Encapsulation of vancomycin and gentamicin within cationic liposomes for inhibition of growth of Staphylococcus epidermidisJ. Drug Target.4181189PubMedGoogle Scholar
  196. 196.
    Frucht-Perry, J., Assil, K. K., Ziegler, E., Douglas, H., Brown, S. I., Schanzlin, D. J., Weinreb, R. N. 1992Fibrin-enmeshed tobramycin liposomes: single application topical therapy of Pseudomonas keratitisCornea11393397PubMedGoogle Scholar
  197. 197.
    Conley, J., Yang, H., Wilson, T., Blasetti, K., Ninno, V., Schnell, G., Park Wong, J. 1997Aerosol delivery of liposome-encapsulated ciprofloxacin: aerosol characterization and efficacy against Francisella tularensis infection in miceAntimicrob. Agents Chemother.4112881292PubMedGoogle Scholar
  198. 198.
    Wong, J. P., Yang, H., Blasetti, K. L., Schnell, G., Conley, J., Schofield, L. N. 2003Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infectionJ. Control. Release92265273PubMedCrossRefGoogle Scholar
  199. 199.
    Rauschmann, M. A., Wichelhous, T. A., Stirnal, V., Dingeldein, E., Zichner, L., Schnettle, R., Alt, V. 2005Nanocrystalline hydroxyapatite and calcium sulphate as biodegradable composite carrier material for local delivery of antibiotics in bone infectionsBiomaterials2626772684PubMedCrossRefGoogle Scholar
  200. 200.
    Jikia, D., Chkhaidze, N., Imedashvili, E., Mgaloblishvili, I., Tsitlanadze, G., Katsarava, R., Glenn Morris, J., Sulakvelidze, A. 2005The use if a novel biodegradable preparation capable of the sustained release of bacteriophages and ciprofloxacin, in the complex treatment of multidrug-resistant Staphylococcus aureus-infection local radiation injuries caused by exposure to Sr 90Clin. Exp. Dermatol.302326PubMedCrossRefGoogle Scholar
  201. 201.
    Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., Sun, Z., Tao, D., Ding, L., Reed, E., Gong, J., Li, Q. Q., Hu, J. 2006Therapeutic effectiveness of bacteriophages in the rescue of mice with extended spectrum beta-lactamase-producing Escherichia coli bacteremiaInt. J. Mol. Med.17347355PubMedGoogle Scholar
  202. 202.
    Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., Sun, Z., Reed, E., Ding, L., Gong, J., Li, Q. Q., Hu, J. 2006Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosaInt. J. Mol. Med.17309317PubMedGoogle Scholar
  203. 203.
    Putnam, D. A. 1996Antisense strategies and therapeutic applicationsAm. J. Health-Syst. Pharm.52151160erratum in Am. J. Health Syst. Pharm.53:325Google Scholar
  204. 204.
    Duzgunes, N., Pretzer, E., Simoes, S., Slepushkin, V., Konopka, K., Flasher, D., Pedroso de Lima, M. C. 1999Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cellsMol. Membr. Biol.16111118PubMedCrossRefGoogle Scholar
  205. 205.
    Martinand-Mari, C., Lebleu, B., Robbins, I. 2003Oligonucleotide-based strategies to inhibit human hepatitis C virusOligonucleotides13348539CrossRefGoogle Scholar
  206. 206.
    Nair, V. 2003Novel inhibitors of HIV integrase: the discovery of potential anti-HIV therapeutic agentsCurr. Pharm. Des.925532565PubMedCrossRefGoogle Scholar
  207. 207.
    Maggon, K., Barik, S. 2004New drugs and treatment for respiratory syncytial virusRev. Med. Virol.14149168PubMedCrossRefGoogle Scholar
  208. 208.
    Irache, J. M., Merodio, M., Arnedo, A., Camapanero, M. A., Mirchahi, M., Espuelas, S. 2005Albumin nanoparticles for the intravitreal delivery of anticytomegaloviral drugsMini Rev. Med. Chem.5293305PubMedGoogle Scholar
  209. 209.
    Markosian, M., Hyde, R. M. 2005Oligonucleotides and polyribonucleotides: a review of antiviral activityAntivir. Chem. Chemother.1691102PubMedGoogle Scholar
  210. 210.
    Duzgunes, N., Simoes, S., Slepushkin, V., Pretzer, E., Clerq, E., Antao, V. P., Collins, M. L., Pedroso de Lima, M. C. 2001Enhanced inhibition of HIV-1 replication in macrophages by antisense oligonucleotides, ribozymes and acyclic nucleoside phosphonate analogs delivered in pH sensitive liposomesNucleosides Nucleotides Nucleic Acids20515523PubMedCrossRefGoogle Scholar
  211. 211.
    Harandi, A. M. 2004The potential of immunostimulatory CpG DNA for inducing immunity against genital herpes: opportunities and challengesJ. Clin. Virol.30207210PubMedGoogle Scholar
  212. 212.
    Mutwiri, G. K., Nichano, A. K., Babiuk, S., Babiuk, L. A. 2004Strategies for enhancing the immunostimulatory effects of CpG oligodeoxynucleotidesJ. Control. Release97117PubMedCrossRefGoogle Scholar
  213. 213.
    Trabattoni, D., Clivio, A., Bray, D. H., Bhagat, L., Beltrami, S., Maffeis, G., Cesana, R., Lowry, P., Lissoni, F., Kandimalla, E. R., Sullivan, T., Agrawal, S., Bartholomew, R., Clerici, M. 2006Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in miceVaccine2414701477PubMedCrossRefGoogle Scholar
  214. 214.
    Bochot, A., Couvreur, P., Fattal, E. 2000Intravitreal administration of antisense oligonucleotides: potential of liposomal deliveryProg. Retin. Eye Res.19131147PubMedCrossRefGoogle Scholar
  215. 215.
    Arnedo, A., Irache, J. M., Merodio, M., Espuelas Millan, M. S. 2004Albumin nanoparticles improved the stability, nuclear accumulation and anticytomegaloviral activity of a phosphodiester oligonucleotideJ. Control. Release94217227PubMedCrossRefGoogle Scholar
  216. 216.
    Bochot, A., Fattal, E., Boutet, V., Deverre, J. R., Jeanny, J. C., Chacun, H., Couvreur, P. 2002Intravitreal delivery of oligonucleotides by sterically stabilized liposomesInvestig. Ophtalmol. Vis. Sci.43253259Google Scholar
  217. 217.
    Fattal, E., Rosa, G., Bochot, A. 2004Gel and solid matrix systems for the controlled delivery of drug carrier-associated nucleic acidsInt. J. Pharm.2772530PubMedCrossRefGoogle Scholar
  218. 218.
    Shi, F., Hoekstra, D. 2004Effective intracellular delivery of oligonucleotides in order to make sense of antisenseJ. Control. Release97189209PubMedCrossRefGoogle Scholar
  219. 219.
    Ropert, C., Lavigno, M., Dubernet, C., Couvreur, P., Malvy, C. 1992Oligonucleotides encapsulated in pH-sensitive liposomes are efficient toward Friend retrovirusBiochem. Biophys. Res. Commun.183879885erratum in: Biochem. Biophys. Res. Commun.192:982 (1993)PubMedCrossRefGoogle Scholar
  220. 220.
    Ropert, C., Malvy, C., Couvreur, P. 1993Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of actionPharm. Res.1014271433PubMedCrossRefGoogle Scholar
  221. 221.
    Ropert, C., Mishal, Z.,Jr., Rodrigues, J. M., Malvy, C., Couvreur, P. 1996Retrovirus budding may contribute a port of entry for drug carriersBiochim. Biophys. Acta13105359PubMedCrossRefGoogle Scholar
  222. 222.
    Berton, M., Turelli, P., Trono, D., Stein, C. A., Allemann, E., Gurny, R. 2001Inhibition of HIV-1 in cell culture by oligonucleotide-loaded nanoparticlesPharm. Res.1810961101PubMedCrossRefGoogle Scholar
  223. 223.
    Zimmer, A. 1999Antisense oligonucleotides delivery with polyhexylcyanoacrylate nanoparticles as carriersMethods18286295PubMedCrossRefGoogle Scholar
  224. 224.
    Lambert, G., Fattal, E., Couvreur, P. 2001Nanoparticulate systems for the delivery of antisense oligonucleotidesAdv. Drug Deliv. Rev.4799112PubMedCrossRefGoogle Scholar
  225. 225.
    Vogel, V., Lochmann, D., Weyermann, J., Mayer, G., Tziatzios, C., Broek, J. A., Haase, W., Wouters, D., Schubert, U. S., Kreuter, J., Zimmer, A., Schubert, D. 2005Oligonucleotide–protamine–albumin nanoparticles: preparation, physical properties, and intracellular distributionJ. Control. Release10399111PubMedCrossRefGoogle Scholar
  226. 226.
    Hu, Q., Shew, C. R., Bally, M. B., Madden, T. D. 2001Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: enhanced cellular uptake and biological effectsBiochim. Biophys. Acta1514113PubMedCrossRefGoogle Scholar
  227. 227.
    Kunizawa, J., Masuda, T., Katayama, K., Yoshikawa, T., Tsutsumi, Y., Akashi, M., Mayumi, T., Nakagawa, S. 2005Fusogenic liposome delivers encapsulated nanoparticles for cytosolic controlled gene releaseJ. Control. Release105344353CrossRefGoogle Scholar
  228. 228.
    Dembri, A., Montisci, M. J., Gantier, J. C., Chacun, H., Ponchel, G. 2001Targeting of 3′-azido 3′-deoxythymidine (AZT)-loaded poly(isohexylcyanoacrylate) nanospheres to the gastrointestinal mucosa and associated lymphoid tissuesPharm. Res.18467473PubMedCrossRefGoogle Scholar
  229. 229.
    Boudad, H., Legrand, P., Appel, M., Coconier, M. H., Ponchel, G. 2001Formulation and cytotoxicity of combined cyclodextrin poly(alkylcyanoacrylate) nanoparticles on Caco-2 cells monolayers intended for oral administration of saquinavirSTP Pharm. Sci.11369375Google Scholar
  230. 230.
    Bender, A. R., Briesen, H., Kreuter, J., Duncan, I. B., Rubasmen-Waigmann, H. 1996Efficiency of nanoparticles as a carrier system for antiviral agents in human immunodeficiency virus-infected human monocytes/macrophages in vitroAntimicrob. Agents Chemother.4014671471PubMedGoogle Scholar
  231. 231.
    Jaeghere, F., Allemann, E., Kubel, F., Galli, B., Cozens, R., Doelker, E., Gurny, R. 2000Oral bioavailability of a poorly water soluble HIV-1 protease inhibitor incorporated into pH-sensitive particles: effect of the particle size and nutritional stateJ. Control. Release68291298PubMedCrossRefGoogle Scholar
  232. 232.
    Meridio, M., Irache, J. M., Valamanesh, F., Mirshahi, M. 2002Ocular disposition and tolerance of ganciclovir-loaded albumin nanoparticles after intravitreal injection in ratsBiomaterials2315871594CrossRefGoogle Scholar
  233. 233.
    Fresta, M., Fontana, G., Bucolo, C., Cavallo, G., Giammona, G., Puglisi, G. 2001Ocular tolerability and in vivo bioavailability of poly(ethylene glycol) (PEG)-coated polyethyl-2-cyanoacrylate nanosphere-encapsulated acyclovirJ. Pharm. Sci.9288297CrossRefGoogle Scholar
  234. 234.
    Sookoian, S. C. 2003New therapies on the horizon for hepatitis CAnn. Hepatol.2164170PubMedGoogle Scholar
  235. 235.
    Papatheodorodis, G. V., Cholongitas, E. 2004Chronic hepatitis C and no response to antiviral therapy: potential current and future therapeutic optionsJ. Viral Hepatitis11287296CrossRefGoogle Scholar
  236. 236.
    Shiffman, M. L. 2004Retreatment of patients who do not respond to initial therapy for chronic hepatitis CClevel. Clin. J. Med.71S13S16CrossRefGoogle Scholar
  237. 237.
    Singh, M., O'Hagan, D. T. 2002Recent advances in vaccine adjuvantsPharm. Res.19715728PubMedCrossRefGoogle Scholar
  238. 238.
    Berzofsky, J. A., Ahlers, J. D., Janik, J., Morris, J., Oh, S., Tarabe, M., Belyakov, I. M. 2004Progress on new vaccine strategies against chronic viral infectionsJ. Clin. Invest.114450462PubMedCrossRefGoogle Scholar
  239. 239.
    O'Hagan, D. T., Rappuoli, R. 2004Novel approaches to vaccine deliveryPharm. Res.2115191530PubMedCrossRefGoogle Scholar
  240. 240.
    Vajdy, M., Srivastava, I., Polo, J., Donnelly, J., O'Hagan, D., Singh, M. 2004Mucosal adjuvants and delivery systems for protein-,DNA- and RNA-based vaccinesImmunol. Cell Biol.82 616627CrossRefGoogle Scholar
  241. 241.
    Kreuter, J. 1995Nanoparticles as adjuvants for vaccinesPharm. Biotechnol.6463472PubMedGoogle Scholar
  242. 242.
    Jiang, Z. H., Koganty, R. R. 2003Synthetic vaccines: the role of adjuvants in immune targetingCurr. Med. Chem.1014231439PubMedCrossRefGoogle Scholar
  243. 243.
    Moser, C., Metcalfe, I. C., Viret, J. F. 2003Virosomal adjuvanted antigen delivery systemsExpert Rev. Vaccines2189196PubMedCrossRefGoogle Scholar
  244. 244.
    Leserman, L. 2004Liposomes as protein carriers in immunologyJ. Liposome Res.14175189PubMedCrossRefGoogle Scholar
  245. 245.
    Copland, M. J., Rades, T., Davies, N. M., Baird, M. A. 2005Lipid based particulate formulations for the delivery of antigensImmunol. Cell Biol.8397105PubMedCrossRefGoogle Scholar
  246. 246.
    Huckriede, A., Bungener, L., Stegmann, T., Daemen, T., Medema, J., Palache, A. M., Wilschut, J. 2005The virosome concept for influenza vaccinesVaccine23S1S1/26S1/38Google Scholar
  247. 247.
    Westerfeld, N., Zurbriggen, R. 2005Peptides delivered by immunostimulating reconstituted influenza virosomesJ. Pept. Sci.11707712PubMedCrossRefGoogle Scholar
  248. 248.
    Kreuter, J., Speiser, P. 1976In vitro studies of poly(methylmethacrylate) adjuvantsJ. Pharm. Sci.6516241627PubMedGoogle Scholar
  249. 249.
    Gregoriadis, G. 1994The immunological adjuvant and vaccine carrier properties of liposomesJ. Drug Target.2351356PubMedGoogle Scholar
  250. 250.
    Aucouturier, J., Dupuis, L., Ganne, V. 2001Adjuvants designed for veterinary and human vaccinesVaccine1926662672PubMedCrossRefGoogle Scholar
  251. 251.
    Daemen, T., Bungener, L., Huckriede, A., Wilschut, J. 2000Virosomes as an antigen delivery systemJ. Liposome Res.10329338Google Scholar
  252. 252.
    Glück, R., Metcalfe, I. C. 2002New technology platforms in the development of vaccines for the futureVaccine20B10B16PubMedCrossRefGoogle Scholar
  253. 253.
    Esposito, S., Marchisio, P., Bosis, S., Lambertini, L., Claut, L., Faelli, N., Bianchi, C., Colombo, G. L., Principi, N. 2006Clinical and economic impact of influenza vaccination on healthy children aged 2–5 yearsVaccine24629635PubMedCrossRefGoogle Scholar
  254. 254.
    Noad, R., Roy, P. 2003Virus-like particles as immunogensTrends Microbiol.11438444PubMedCrossRefGoogle Scholar
  255. 255.
    Garcea, R. L., Gissmann, L. 2004Virus-like particles as vaccines and vessels for the delivery of small moleculesCurr. Opin. Biotechnol.15513517PubMedCrossRefGoogle Scholar
  256. 256.
    Storni, T., Ruedl, C., Schwarz, K., Schwendener, R. A., Renner, W. A., Bachmann, M. F. 2004Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effectsJ. Immunol.17217771785PubMedGoogle Scholar
  257. 257.
    Morein, B., Hu, K. F., Abusugra, I. 2004Current status and potential application of ISCOMs in veterinary medicineAdv. Drug Deliv. Rev.5613671382PubMedCrossRefGoogle Scholar
  258. 258.
    Hoegen, P. 2001Synthetic biomimetic supra molecular Biovector™ (SMBV™) particles for nasal vaccine deliveryAdv. Drug Deliv. Rev.51113125CrossRefGoogle Scholar
  259. 259.
    Debin, A., Kravtzoff, R., Santiago, J., Cazales, L., Sperandio, S., Melber, K., Janowicz, Z., Betbeder, D., Moynier, M. 2002Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responsesVaccine2027522763PubMedCrossRefGoogle Scholar
  260. 260.
    Baudner, B. C., Balland, O., Guiliani, M. M., Hoegen, P., Rappuoli, R., Betbeder, D., Giudice, G. 2002Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered nanoparticlesInfect. Immun.7047854790PubMedCrossRefGoogle Scholar
  261. 261.
    Jung, T., Kamm, W., Breitenbach, A., Hungerer, K. D., Hundt, E., Kissel, T. 2001Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinylalcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in micePharm. Res.18352360PubMedCrossRefGoogle Scholar
  262. 262.
    Conacher, M., Alexander, J., Brewer, J. M. 2001Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes)Vaccine1929652974PubMedCrossRefGoogle Scholar
  263. 263.
    Gluck, R. 2002Intranasal immunization against influenzaJ. Aerosol Med.15221218PubMedCrossRefGoogle Scholar
  264. 264.
    Holmgren, J., Czerkinsky, C., Erikssen, K., Mharandi, A. 2003Mucosal immunisation and adjuvants: a brief overview of recent advances and challengesVaccine21S89S95PubMedCrossRefGoogle Scholar
  265. 265.
    Panyam, J., Labhasetwar, V. 2003Biodegradable nanoparticles for drug and gene delivery to cells and tissueAdv. Drug Deliv. Rev.55329347PubMedCrossRefGoogle Scholar
  266. 266.
    Koping-Hoggard, M., Sanchez, A., Alonso, M. J. 2005Nanoparticles as carriers for nasal vaccine deliveryExpert Rev. Vaccines4185196PubMedCrossRefGoogle Scholar
  267. 267.
    Florence, A. T. 1997The oral absorption of micro- and nanoparticulates: neither exceptional nor unusualPharm. Res.14259266PubMedCrossRefGoogle Scholar
  268. 268.
    Mcclean, S., Prosser, F., Meehan, F., O'Malley, D., Clarke, N., Ramtoola, Z., Brayden, D. 1998Binding and uptake of biodegradable poly-dl-lactide micro- and nanoparticles in intestinal epitheliaEur. J. Pharm. Sci.6153163PubMedCrossRefGoogle Scholar
  269. 269.
    Jung, T., Kamm, W., Breitenbach, A., Kaiserling, E., Xiao, J. X., Kissel, T. 2000Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake?Eur. J. Pharm. Biopharm.50147160PubMedCrossRefGoogle Scholar
  270. 270.
    Fattal, E., Pecquet, S., Couvreur, P., Andremont, A. 2002Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigensInt. J. Pharm.2421524PubMedCrossRefGoogle Scholar
  271. 271.
    Shakweh, M., Besnard, M., Nicolas, V., Fattal, E. 2005Poly(lactide-co-glycolide) particles of different physicochemical properties and their uptake by Peyer's patches in miceEur. J. Pharm. Biopharm.61113PubMedCrossRefGoogle Scholar
  272. 272.
    Fifis, T., Gamvrellis, A., Crimeen-Irwin, B., Pietersz, G. A., Li, J., Mottram, P. L., McKenzie, I. F., Plebanski, M. 2004Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumorsJ. Immunol.17331483154PubMedGoogle Scholar
  273. 273.
    Mann, J. F., Ferro, V. A., Mullen, A. B., Tetley, L., Mullen, M., Carter, K. C., Alexander, J., Stimson, W. H. 2004Optimisation of a lipid based oral delivery system containing A/Panama influenza haemagglutininVaccine2224252429PubMedCrossRefGoogle Scholar
  274. 274.
    Gluck, U., Gebbers, J. O., Gluck, R. 1999Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteersJ. Virol.7377807786PubMedGoogle Scholar
  275. 275.
    Mutsch, M., Zhou, W., Rhodes, P., Bopp, M., Chen, R. T., Linder, T., Spyr, C., Steffen, R. 2004Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in SwitzerlandN. Engl. J. Med.350896903PubMedCrossRefGoogle Scholar
  276. 276.
    Berzofsky, J. A., Ahlers, J. D., Belyakov, I. M. 2001Strategies for designing and optimizing new generation vaccinesNat. Rev. Immunol.1209219PubMedCrossRefGoogle Scholar
  277. 277.
    Diwan, M., Elamanchili, P., Lane, H., Gainer, A., Samuel, J. 2003Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responsesJ. Drug Target.11495507PubMedCrossRefGoogle Scholar
  278. 278.
    Jiao, X., Wang, R. Y., Qiu, Q., Alter, H. J., Shih, J. W. 2004Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomesJ. Gen. Virol.8515451553PubMedCrossRefGoogle Scholar
  279. 279.
    Kerkmann, M., Costa, C. L., Richter, C., Rothenfusser, S., Battiany, J., Hornung, V., Johnson, J., Englert, S., Ketterer, T., Heckl, W., Thalhammer, S., Endres, S., Hartmann, G. 2005Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cellsJ. Biol. Chem.28080868093PubMedCrossRefGoogle Scholar
  280. 280.
    Manoj, S., Babiuk, L. A., Drunen Littel-van den Hurk, V. 2004Approaches to enhance the efficacy of DNA vaccinesCrit. Rev. Clin. Lab. Sci.41139PubMedCrossRefGoogle Scholar
  281. 281.
    Cui, Z., Mumper, R. J. 2002Genetic immunization using nanoparticles engineered from microemulsion precursorPharm. Res.19939946PubMedCrossRefGoogle Scholar
  282. 282.
    Mao, H. Q., Roy, K., Troung-La, V. L., Janes, K. A., Lin, K. Y., Wang, Y., August, J. T., Leong, K. W. 2001Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiencyJ. Control. Release70399421PubMedCrossRefGoogle Scholar
  283. 283.
    Bivas-Benita, M., Ottenhoff, T. H., Junginger, H. E., Borchard, G. 2005Pulmonary DNA vaccination: concepts, possibilities and perspectivesJ. Control. Release107129PubMedCrossRefGoogle Scholar
  284. 284.
    Locher, C. P., Putnam, D., Langer, R., Witt, S. A., Ashlock, B. M., Levy, J. A. 2003Enhancement of a human immunodeficiency virus env DNA vaccine using a novel polycationic nanoparticle formulationImmunol. Lett.906770PubMedCrossRefGoogle Scholar
  285. 285.
    Cui, Z., Han, S. J., Padinjarae Vangasseri, D., Huang, L. 2005Immunostimulation mechanism of LPD nanoparticle as a vaccine carrierMol. Pharmacol.22228Google Scholar
  286. 286.
    Verrier, B. 2005Therapeutic vaccination for chronic infectious diseases: lessons from HIV-1J. Clin. Virol.34S9S12PubMedCrossRefGoogle Scholar
  287. 287.
    Michel, M. L., Mancini-Bourgine, M. 2005Therapeutic vaccination against chronic hepatitis B virus infectionJ. Clin. Virol.34S108S114PubMedCrossRefGoogle Scholar
  288. 288.
    World Health Organisation. Diabetes, http://www.who.int/mediacentre/factsheets/fs138/en/index.html, (accessed Nov 15, 2005) part of http://www.who.int (accessed Nov 15, 2005).
  289. 289.
    Tanaka, S. I., Yamakawa, T., Aoki, I., Okuda, K., Mobbs, C. 2004Daily nasal inoculation with the insulin gene ameliorates diabetes in miceDiabetes Res. Clin. Pract.6319PubMedCrossRefGoogle Scholar
  290. 290.
    Gomez-Perez, F., Rull, J. A. 2005Insulin therapy: current alternativesArch. Med. Res.3625872PubMedCrossRefGoogle Scholar
  291. 291.
    Muno-Torres, M., Alonso, G., Raya, M. P. 2004Calcitonin therapy in osteoporosisTreat. Endocrinol.3117132CrossRefGoogle Scholar
  292. 292.
    Prego, C., Garcia, M., Torres, D., Alonso, M. J. 2005Transmucosal macromolecular drug deliveryJ. Control. Release101151162PubMedCrossRefGoogle Scholar
  293. 293.
    Cao, Y., Lam, L. 2002Projections for insulin treatment for diabeticsDrugs Today38419427CrossRefPubMedGoogle Scholar
  294. 294.
    Saffran, M., Pansky, B., Colin Budd, G., Williams, F. E 1997Insulin and the gastrointestinal tractJ. Control. Release468998CrossRefGoogle Scholar
  295. 295.
    Dapergolas, G., Gregoriadis, G. 1976Hypoglycemic effect of liposome-entrapped insulin administered intragastrically into ratsLancet2824827PubMedCrossRefGoogle Scholar
  296. 296.
    Patel, H. M., Ryman, B. E. 1976Oral administration if insulin by encapsulation in liposomesFEBS Lett.626063PubMedCrossRefGoogle Scholar
  297. 297.
    Woodley, J. F. 1985Liposomes for oral administration of drugsCrit. Rev. Ther. Drug Carr. Syst.2118Google Scholar
  298. 298.
    Damgé, C., Michel, C., Aprahamian, M., Couvreur, P. 1988New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrierDiabetes37246251PubMedGoogle Scholar
  299. 299.
    Spangler, R. S. 1990Insulin administration via liposomesDiabetes Care13911922PubMedGoogle Scholar
  300. 300.
    Carino, G. P., Mathiowitz, E. 1999Oral insulin deliveryAdv. Drug Deliv. Rev.35249257PubMedCrossRefGoogle Scholar
  301. 301.
    Vauthier, C., Seiller, M., Weingarten, C., Couvreur, P. 1999Contribution to the development of oral dosage form for insulin deliverySTP Pharm. Sci.9391396Google Scholar
  302. 302.
    Kisel, M. A., Kulik, L. N., Tsybovsky, I. S., Vlasov, A. P., Vorob'yov, M. S., Kholodava, E. A., Zabarovskaca, Z. V. 2001Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the ratInt. J. Pharm.216105114PubMedCrossRefGoogle Scholar
  303. 303.
    Couvreur, P., Barratt, G., Fattal, E., Legrand, P., Vauthier, C. 2002Nanocapsule technology: a reviewCrit. Rev. Ther. Drug Carr. Syst.1999134CrossRefGoogle Scholar
  304. 304.
    Watnasirichaikul, S., Rades, T., Tucker, I. G., Davies, N. W. 2002In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsionJ. Pharm. Pharmacol.54473480PubMedCrossRefGoogle Scholar
  305. 305.
    Katayama, K., Kato, Y., Onishi, H., Nagai, T., Machida, Y. 2003Double liposomes: hypoglycemic effects of liposomal insulin on normal ratsDrug Dev. Ind. Pharm.29725731PubMedCrossRefGoogle Scholar
  306. 306.
    Csaba, N., Gonzalez, L., Sanchez, A., Alonso, M. J. 2004Design and characterisation of new nanoparticulate polymer blends for drug deliveryJ. Biomater. Sci. Polym. Ed.1511371151PubMedCrossRefGoogle Scholar
  307. 307.
    Simon, M., Wittmar, M., Kissel, T., Linn, T. 2005Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(l-lactide): bioavailability and nasal tolerability in ratsPharm. Res.2218791886PubMedCrossRefGoogle Scholar
  308. 308.
    Mao, S., Germerhaus, O., Fischer, D., Linn, T., Schnepf, R., Kissel, T. 2005Uptake and transport of PEG-graft-trimethyl-chitosan copolymer–insulin nanocomplexes by epithelias cellsPharm. Res.2220582068PubMedCrossRefGoogle Scholar
  309. 309.
    Garcia-Fuentes, M., Torres, D., Alonso, M. J. 2005New surface modified lipid nanoparticles as delivery vehicle for salmon calcitoninInt. J. Pharm.296122132PubMedCrossRefGoogle Scholar
  310. 310.
    Zhang, N., Ping, Q. N., Huang, G. H., Xu, W. F. 2005Investigation of lectin-modified insulin liposomes as carriers for oral administrationInt. J. Pharm.294247259PubMedCrossRefGoogle Scholar
  311. 311.
    Aprahamian, M., Michel, C., Humbert, W., Devissaguet, J. P., Damgé, C. 1987Transmucosal passage of poly(alkylcyanoacrylate) nanocapsules as a new drug carrier in the small intestineBiol. Cell616976PubMedGoogle Scholar
  312. 312.
    Pinto-Alphandary, H., Aboubakar, M., Jaillard, D., Couvreur, P., Vauthier, C. 2003Visualization of insulin-loaded nanocapsules: in vitro and in vivo studies after oral administration to ratsPharm. Res.2010711084PubMedCrossRefGoogle Scholar
  313. 313.
    Florence, A. T. 2004Issues in oral nanoparticle drug carrier uptake and targetingJ. Drug Target.126570PubMedCrossRefGoogle Scholar
  314. 314.
    Couvreur, P., Lenaerts, V., Kante, B., Roland, M., Speiser, P. 1980Oral and parenteral administration of insulin associated to hydrolysable nanoparticlesActa Pharm. Technol.26220Google Scholar
  315. 315.
    Damgé, C., Vranckx, H., Balschmidt, P., Couvreur, P. 1997Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulinJ. Pharm. Sci.8614031409PubMedCrossRefGoogle Scholar
  316. 316.
    Mesiha, M. S., Sidhom, M. B., Fasipe, B. 2005Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticlesInt. J. Pharm.288289293PubMedCrossRefGoogle Scholar
  317. 317.
    Damgé, C., Hillaire-buys, D., Puech, R., Hilozel, A., Michel, C., Ribes, G. 1995Effect of orally administered insulin nanocapsules in normal and diabetic ratsDiab. Nutr. Metab.839Google Scholar
  318. 318.
    Lowe, P. J., Temple, C. S. 1994Calcitonin and insulin in isobutylcyanoacrylate nanocapsules: protection against proteases and effect on intestinal absorption in ratsJ. Pharm. Pharmacol.46547552PubMedGoogle Scholar
  319. 319.
    Aboubakar, M., Couvreur, P., Pinto-Alphandary, H., Gouritin, B., Lacour, B., Farinotti, R., Puisieux, F., Vauthier, C. 2000Insulin-loaded nanocapsules for oral administration; in vitro and in vivo investigationDrug Dev. Res.49109117CrossRefGoogle Scholar
  320. 320.
    Cournarie, F., Auchère, D., Chevenne, D., Lacour, B., Seiller, M., Vauthier, C. 2002Absorption and efficiency of insulin after oral administration of insulin-loaded nanocapsules in diabetic ratsInt. J. Pharm.242325328PubMedCrossRefGoogle Scholar
  321. 321.
    Carino, G. P., Jacob, J. S., Mathiowitz, E. 2000Nanosphere based oral insulin deliveryJ. Control. Release65261269PubMedCrossRefGoogle Scholar
  322. 322.
    Sakuma, S., Hayashi, M., Akashi, M. 2001Design of nanoparticles composed of graft copolymers for oral peptide deliveryAdv. Drug Deliv. Rev.472137PubMedCrossRefGoogle Scholar
  323. 323.
    Sullivan, C. O., Birkinshaw, C. 2004In vitro degradation of insulin-loaded poly(n-butylcyanoacrylate) nanoparticlesBiomaterials2543754382PubMedCrossRefGoogle Scholar
  324. 324.
    Vila, A., Sanchez, A., Tobio, M., Calvo, P., Alonso, M. J. 2002Design of biodegradable particles for protein deliveryJ. Control. Release781524PubMedCrossRefGoogle Scholar
  325. 325.
    Hillery, A. M., Jani, P. U., Florence, A. T. 1994Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60 nm polystyrene particlesJ. Drug Target.2151156PubMedGoogle Scholar
  326. 326.
    Mathiowitz, E., Jacob, J. S., Jong, Y. S., Carino, G. P., Chickering, D. E., Chaturvedi, P., Santos, C. A., Vijayaraghavan, K., Montgomery, S., Bassett, S., Morrell, C. 1997Biologically erodable microspheres as potential oral drug delivery systemsNature386410414PubMedCrossRefGoogle Scholar
  327. 327.
    Delie, F. 1998Evaluation of nano- and microparticle uptake by the gastrointestinal tractAdv. Drug Deliv. Rev.34221233PubMedCrossRefGoogle Scholar
  328. 328.
    Behrens, L., Pena, A. I., Alonso, M. J., Kissel, T. 2002Comparative uptake studies of bioadhesive and non bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transportPharm. Res.1911851193PubMedCrossRefGoogle Scholar
  329. 329.
    Degim, Z., Unal, N., Essiz, D., Abbasoglu, U. 2004The effect of various liposome formulations on insulin penetration across Caco-2 cell monolayerLife Sci.7528192827PubMedCrossRefGoogle Scholar
  330. 330.
    Ponchel, G., Irache, J. 1998Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tractAdv. Drug Deliv. Rev.34191219PubMedCrossRefGoogle Scholar
  331. 331.
    Clissold, S. P., Fitton, A., Chrisp, P. 1991Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with agingDrugs Aging1405423PubMedGoogle Scholar
  332. 332.
    Turker, S., Onur, E., Ozer, Y. 2004Nasal route and drug delivery systemsPharm. World Sci.26137142PubMedCrossRefGoogle Scholar
  333. 333.
    Fernandez-Urrusuno, R., Calvo, P., Rumunan-Lopez, C., Vila-Lato, J. L., Alonso, M. J. 1999Enhancement of nasal absorption of insulin using chitosan nanoparticlesPharm. Res.1615761581PubMedCrossRefGoogle Scholar
  334. 334.
    Vila, A., Gill, H., McCallion, O., Alonso, M. J. 2004Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating densityJ. Control. Release98231244PubMedCrossRefGoogle Scholar
  335. 335.
    Simon, M., Wittmar, M., Kissel, T., Linn, T. 2005Insulin containing nanocomplexes formed by self-assembly from biodegradable amine-modified poly(vinyl alcohol)-graft-poly(l-lactide): bioavailability and nasal tolerability in ratsPharm. Res.2218791886PubMedCrossRefGoogle Scholar
  336. 336.
    C. Vermehren, S. Frokjaer, T. Aurstad, and J. Hansen. Lung surfactant as a drug delivery system. Int. J. Pharm. 307:89–92 (2006).Google Scholar
  337. 337.
    Li, Y., Mitra, A. K. 1996Effects of phospholipid chain length, concentration, charge and vesicle size on pulmonary insulin absorptionPharm. Res.137679PubMedCrossRefGoogle Scholar
  338. 338.
    Blanchard, J., Coleman, J., D'Abreu Hayling, C., Ghaderi, R., Haeberlin, B., Hart, J., Jensen, S., Malcolmson, R., Mittelman, S., Nagao, L. M., Sekulic, S., Snodgrass-Pilla, C., Sundahl, M., Thompson, G., Wolff, R. 2004Foreign particles testing in orally inhaled and nasal drug productsPharm. Res.2121372147PubMedCrossRefGoogle Scholar
  339. 339.
    Wilson, G. L., Leiter, E. H. 1990Streptozotocin interactions with pancreatic beta cells and the induction of insulin-dependent diabetesCurr. Top. Microbiol. Immunol.1562754PubMedGoogle Scholar
  340. 340.
    Blondel, O., Portha, B. 1989Early appearance of in vivo insulin resistance in adult streptozotocin-injected ratsDiab. Metab.15382387Google Scholar
  341. 341.
    Mordes, J. P., Cortell, R., Clanjenhorn, E. P., Rossini, A. A., Greiner, D. L. 2004Rat models of type 1 diabetes: genetics, environment, and autoimmunityILAR J.45278291PubMedGoogle Scholar
  342. 342.
    Ubrich, N., Schmidt, C., Bodmeier, R., Hoffman, M., Maincent, P. 2005Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS and RL nanoparticlesInt. J. Pharm.2888168175Google Scholar
  343. 343.
    Milani, J. K., Pleyer, U., Dukes, A., Chou, H. J., Lutz, S., Ruckert, D., Schmidt, K. H., Mondino, B. J. 1993Prolongation of corneal allograft survival with liposome-encapsulated cyclosporin in the rat eyeOphthalmology100890896PubMedGoogle Scholar
  344. 344.
    Campos, A. M., Sanchez, A., Alonso, M. J. 2001Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin AInt. J. Pharm.224159168PubMedCrossRefGoogle Scholar
  345. 345.
    Lallemand, F., Felt-Baeyens, O., Bessenghir, K., Behar-Cohen, F., Gurny, R. 2003Cyclosporin A delivery to the eye: a pharmaceutical challengeEur. J. Pharm. Biopharm.56307318PubMedCrossRefGoogle Scholar
  346. 346.
    Qaddoumi, M. G., Ueda, H., Yang, J., Dvada, J., Labhasetwar, V., Lee, V. H. 2004The characteristics and mechanisms of uptake of PLGA nanoparticles in rabbit conjunctival epithelial cell layersPharm. Res.21641648PubMedCrossRefGoogle Scholar
  347. 347.
    Schwartz, M. 2001Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disordersCell Mol. Neurobiol.21617627PubMedCrossRefGoogle Scholar
  348. 348.
    Schmidt, J., Metselaar, J. M., Wauben, M. H., Toyka, K. V., Storm, G., Gold, R. 2003Drug targeting by long-circulating liposomal glucocorticosteroids increases therapeutic efficacy in a model of multiple sclerosisBrain12618951904PubMedCrossRefGoogle Scholar
  349. 349.
    Kozac, Y., Andrieux, K., Villarroya, H., Klein, C., Thillaye-Goldenberg, B., Naud, M. C., Garcia, E., Couvreur, P. 2004Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitisEur. J. Immunol.3437023712CrossRefGoogle Scholar
  350. 350.
    Schwartz, M. 2004Vaccination for glaucoma: dream or reality?Brain Res. Bull.62481484PubMedCrossRefGoogle Scholar
  351. 351.
    Billotey, C., Aspord, C., Beuf, O., Piaggio, E., Gazeau, F., Janier, M. F., Thivolet, C. 2005T-cell homing to the pancreas in autoimmune mouse models of diabetes: in vivo MR imagingRadiology236579587PubMedGoogle Scholar
  352. 352.
    Vauthier, C., Fattal, E., Labarre, D. 2004

    From polymer chemistry and physicochemistry to nanoparticulate drug carrier design and applications

    Yaszemski, M. J.Trantolo, D. J.Lewamdrowski, K. U.Hasirci, V.Altobelli, D. E.Wise, D. L. eds. Biomaterial Handbook—Advanced Applications of Basic Sciences and BioengineeringMarcel Dekker, Inc.New York, USA563598
    Google Scholar
  353. 353.
    Ammoury, N., Fessi, H., Devissaguet, J. P., Dubrasquet, M., Benita, S. 1991Jejunal absorption, pharmacological activity, and pharmacokinetic evaluation of indomethacin-loaded poly(d,l-lactide) and poly(isobutyl-cyanoacrylate) nanocapsules in ratsPharm. Res.8101105PubMedCrossRefGoogle Scholar
  354. 354.
    Fawaz, F., Bonini, F., Guyot, M., Lagueny, A. M., Fessi, H., Devissaguet, J. P. 1993Influence of poly(dl-lactide) nanocapsules on the biliary clearance and enterohepatic circulation of indomethacin in the rabbitPharm. Res.10750756PubMedCrossRefGoogle Scholar
  355. 355.
    Guterres, S. S., Fessi, H., Barratt, G., Puisieux, F., Devissaguet, J. P. 1995Poly(d,l-lactide) nanocapsules containing non-steroidal anti-inflammatory drugs: gastrointestinal tolerance following intravenous and oral administrationPharm. Res.1215451547PubMedCrossRefGoogle Scholar
  356. 356.
    Al-Muhammed, J., Ozer, A. Y., Ercan, M. T., Hincal, A. A. 1996In-vivo studies on dexamethasone sodium phosphate liposomesJ. Microencapsul.13293306PubMedGoogle Scholar
  357. 357.
    Guterres, S. S., Fessi, H., Barratt, G., Puisieux, F., Devissaguet, J. P. 2000Poly(rac-lactide) nanocapsules containing diclofenac: protection against muscular damage in ratsJ. Biomater. Sci., Polym. Ed.1113471355CrossRefGoogle Scholar
  358. 358.
    Calvo, P., Alonso, M. J., Vila-Jato, J. L., Robinson, J. R. 1996Improved ocular bioavailability of indomethacin by novel ocular drug carriersJ. Pharm. Pharmacol.4811471152PubMedGoogle Scholar
  359. 359.
    Bucolo, C., Maltese, A., Plugisi, G., Pignatello, R. 2002Enhanced ocular anti-inflammatory activity of ibuprofen carried by an Eudragit RS100 nanoparticle suspensionOphthalmic Res.34319323PubMedCrossRefGoogle Scholar
  360. 360.
    Jiang, B., Hu, L., Gao, C., Shen, J. 2005Ibuprofen-loaded nanoparticles prepared by a co-precipitation method and their release propertiesInt. J. Pharm.304220230PubMedCrossRefGoogle Scholar
  361. 361.
    Heffernan, M. J., Murthy, N. 2005Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicleBioconjug. Chem.1613401342PubMedCrossRefGoogle Scholar
  362. 362.
    Galindo-Rodriguez, S. A., Puel, F., Briancon, S., Allemann, E., Doelker, E., Fessi, H. 2005Comparative scale-up of three methods for producing ibuprofen-loaded nanoparticlesEur. J. Pharm. Sci.25357367PubMedCrossRefGoogle Scholar
  363. 363.
    Merisko-Liversidge, E., Liversidge, G. G., Cooper, E. R. 2003Nanosizing: a formulation approach for poorly-water-soluble compoundsEur. J. Pharm. Sci.18113120PubMedCrossRefGoogle Scholar
  364. 364.
    Rasenak, N., Hartenhauer, H., Muller, B. W. 2003Microcrystals for dissolution rate enhancement of poorly water-soluble drugsInt. J. Pharm.254137145CrossRefGoogle Scholar
  365. 365.
    Eidelman, A., Weiss, J. M., Lau, J., Carr, D. B. 2005Topical anaesthetics for dermal instrumentation: a systematic review of randomized, controlled trialsAnn. Emerg. Med.46343351PubMedCrossRefGoogle Scholar
  366. 366.
    Taddio, A., Soin, H. K., Schuh, S., Koren, G., Scolnik, D. 2005Liposomal lidocaine to improve procedural success rates and reduce procedural pain among children: a randomized controlled trialCMAJ17216911695PubMedGoogle Scholar
  367. 367.
    Viscusi, E. R. 2004Emerging techniques in the treatment of postoperative painAm. J. Health-Syst. Pharm.61S11S14PubMedGoogle Scholar
  368. 368.
    Vuscusi, E. R. Martin, G. Hartrick, C. T. Singla, N. Manvelian, G. The EREM Study group2005Forty-eight hours of postoperative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulationAnesthesiology10210141022CrossRefGoogle Scholar
  369. 369.
    Grant, S. A. 2002The holy grail: long acting local anaesthetics and liposomesBest Pract. Res. Clin. Anaesthesiol.16345352PubMedCrossRefGoogle Scholar
  370. 370.
    Mantripragada, S. 2002A lipid based depot (DepoFoam technology) for sustained release drug deliveryProg. Lipid Res.41392406PubMedCrossRefGoogle Scholar
  371. 371.
    Lamprecht, A., Saumet, J. L., Roux, J., Benoit, J. P. 2004Lipid nanocarriers as drug delivery system for ibuprofen in pain treatmentInt. J. Pharm.278407414PubMedCrossRefGoogle Scholar
  372. 372.
    Betbeder, D., Sperandio, S., Latapie, J. P., Nadai, J., Etienn, A., Zajac, J. M., Frances, B. 2000Biovector™ nanoparticles improve antinociceptive efficacy of nasal morphinePharm. Res.17743748PubMedCrossRefGoogle Scholar
  373. 373.
    Wolka, A. M., Huber, J. D., Davis, T. P. 2003Pain and the blood–brain barrier: obstacles to drug deliveryAdv. Drug Deliv. Rev.559871006PubMedCrossRefGoogle Scholar
  374. 374.
    Pardridge, W. M. 1999Vector-mediated drug delivery to the brainAdv. Drug Deliv. Rev.36299321PubMedCrossRefGoogle Scholar
  375. 375.
    Olivier, J. C. 2005Drug transport to brain with targeted nanoparticlesNeuroRx2108119PubMedCrossRefGoogle Scholar
  376. 376.
    Pardridge, W. M. 2005Drug and gene targeting to the brain via blood–brain barrier receptor-mediated transport systemsInt. Congr. Ser.12774962CrossRefGoogle Scholar
  377. 377.
    Kreuter, J. 2004Influence of the surface properties on nanoparticle-mediated transport of drugs to the brainJ. Nanosci. Nanotechnol.4484488PubMedCrossRefGoogle Scholar
  378. 378.
    Brandl, M., Gregoriadis, G. 1994Entrapment of haemoglobin into liposomes by the dehydration–rehydration method: vesicle characterization and in vivo behaviourBiochim. Biophys. Acta11966575PubMedCrossRefGoogle Scholar
  379. 379.
    Sakai, H., Masada, H. Y., Horinouchi, , Ikeda, E., Sou, K., Takeoka, S., Suematsu, M., Takaori, M., Kobayashi, K., Tsuchida, E. 2004Physiological capacity of the reticuloendothelial system for the degradation of hemoglobin vesicles (artificial oxygen carriers) after massive intravenous doses by daily repeated infusions for 14 daysJ. Pharmacol. Exp. Ther.311874884PubMedCrossRefGoogle Scholar
  380. 380.
    Takaori, M. 2005Approach to clinical trial considering medical ethics and efficacy for HbV, liposome encapsulated hemoglobin vesicleArtif. Cells Blood Substit. Immobil. Biotechnol.33 6573PubMedGoogle Scholar
  381. 381.
    Chang, T. M. S., D'Agnillo, F., Yu, W. P., Razack, S. 2000Two future generations of blood substitutes based on polyhemoglobin–SOD–catalase and nanoencapsulationAdv. Drug Deliv. Rev.40213218PubMedCrossRefGoogle Scholar
  382. 382.
    Khopade, A. J., Khopade, S., Jain, N. K. 2002Development of hemoglobin aquasomes from spherical hydroxyapatite cores precipitated in the presence of half-generation poly(amidoamine) dendrimerInt. J. Pharm.241145154PubMedCrossRefGoogle Scholar
  383. 383.
    Chauvierre, C., Marden, M. C., Vauthier, C., Labarre, D., Couvreur, P., Leclerc, L. 2004Heparin coated poly(alkylcyanoacrylate) nanoparticles coupled to hemoglobin: a new oxygen carrierBiomaterials2530813086PubMedCrossRefGoogle Scholar
  384. 384.
    Chang, T. M., Powanda, D., Yu, W. P. 2003Analysis of polyethylene–glycol–polylactide nano-dimension artificial red blood cells maintaining systemic hemoglobin levels and prevention of methemoglobin formationArtif. Cells Blood Substit. Immobil. Biotechnol.31231247PubMedCrossRefGoogle Scholar
  385. 385.
    Sakai, H., Masada, Y., Onuma, H., Takeoka, S., Tsuchida, E. 2004Reduction of methemoglobin via electron transfer from photoreduced flavin: restoration of O2-binding of concentrated hemoglobin solution coencapsulated in phospholipid vesiclesBioconjug. Chem.1510371045PubMedCrossRefGoogle Scholar
  386. 386.
    Passirani, C., Barratt, G., Devissageut, J. P., Labarre, D. 1998Long-circulating nanoparticles bearing heparin or dextran covalently bound to poly(methyl methacrylate)Pharm. Res.1510461050PubMedCrossRefGoogle Scholar
  387. 387.
    Flynn, T., Wei, C. 2005The pathway to commercialization for nanomedicineNanomed. Nanotechnol., Biol. Med.14751CrossRefGoogle Scholar
  388. 388.
    Sangro, B. 2005Refined tools for the treatment of hepatocellular carcinomaJ. Hepatol.42629631PubMedCrossRefGoogle Scholar
  389. 389.
    C. H. Dubin. Drug discovery and delivery: tear down those walls. Drug Delivery Technology. 3#5 (2005). http://www.drugdeliverytech.com/cgi-bin/article.cgi?idArticle=329 (accessed 08/09/2005), part of http://www.drugdeliverytech.com (accessed 08/09/2005).
  390. 390.
    Bennett, C. L., Calhoun, E. A. 2004Pharmacoeconomics of liposomal anthracycline therapySemin. Oncol.31191195PubMedCrossRefGoogle Scholar
  391. 391.
    F. J. Martin and T. Huang. Stealth liposomal technology: current therapies and future directions. Drug Delivery Technology. 3#5 (2005). http://www.drugdeliverytech.com/cgi-bin/article.cgi?idArticle=155 (accessed 08/09/2005), part of http://www.drugdeliverytech.com (accessed 08/09/2005).
  392. 392.
    http://ClinicalTrials.gov/ct/gui/action/GetStudy (accessed 12/09/2005) part of http://ClinicalTrials.gov (accessed 12/09/2005).
  393. 393.
    Galanbor, Z., Marashi, S. A., Rajbar, B. 2005Nanotechnology helps medicine: nanoscale swimmers and their future applicationsMed. Hypotheses65198199CrossRefGoogle Scholar
  394. 394.
    Cavalcanti, A., Freitas, R. A. 2005Nanorobotics control design: a collective behavior approach for medicineIEEE Trans. Nanobiosci.4133140CrossRefGoogle Scholar
  395. 395.
    Kubik, T., Bogunia-Kubik, K., Sugisaka, M. 2005Nanotechnology on duty in medical applicationsCurr. Pharm. Biotechnol.61733PubMedGoogle Scholar
  396. 396.
    M. D. Burke. Drug delivery technology assessment: the eight assessment gates. Drug Delivery Technology. 3#5 (2005). http://www.drugdeliverytech.com/cgi-bin/article.cgi?idArticle=343 (accessed 08/09/2005), part of http://www.drugdeliverytech.com (accessed 08/09/2005).
  397. 397.
    Bastani, B., Fernandez, D. 2002Intellectual property rights in nanotechnologyThin Solid Films420–421472477CrossRefGoogle Scholar
  398. 398.
    N. Sadrieh. FDA perspective on nanomaterial containing products. Nanobusiness Conference May 2005. http://www.fda.gov/nanotechnology/powerpoint_conversions/May05_files/handout/index.html (accessed 6 September 2005), part of http://www.fda.gov (accessed 6 September 2005).
  399. 399.
    Nanotechnologies: A Preliminary Risk Analysis on the Basis of a Workshop Organized by the Health and Consumer Protection Directorate General of the European Commission. European Community 2004. http://europa.eu.int/comm/health/ph_risk/events_risk_en.htm (accessed 22 December 2005), part of http://europa.eu.int (accessed 22 December 2005).
  400. 400.
    Borm, P. J., Kreyling, W. 2004Toxicological hazards of inhaled nanoparticles—potential implications for drug deliveryJ. Nanosci. Nanotechnol.4521531PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Laboratoire de Physico-chimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612Université de Paris SudChatenay-Malabry CedexFrance

Personalised recommendations